



**HAL**  
open science

## Metabolic reprogramming in cancer cells, consequences on pH and tumour progression: Integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer treatment

Jean-François Dumas, Lucie Brisson, Stephan Chevalier, Karine Mahéo, Gaëlle Fromont, Driffa Moussata, Pierre Besson, Sébastien Roger

### ► To cite this version:

Jean-François Dumas, Lucie Brisson, Stephan Chevalier, Karine Mahéo, Gaëlle Fromont, et al.. Metabolic reprogramming in cancer cells, consequences on pH and tumour progression: Integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer treatment. *Seminars in Cancer Biology*, 2017, The new pH-centric Anticancer Paradigm in Oncology and Medicine, 43, pp.90-110. 10.1016/j.semcancer.2017.03.004 . hal-01907572

**HAL Id: hal-01907572**

**<https://univ-tours.hal.science/hal-01907572>**

Submitted on 20 Aug 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Invited Review in *Seminars in Cancer Biology*

Special Issue: “The new pH-centric paradigm in basic and clinical oncology”

(Guest editors: Prof. Salvador Harquindey & Prof. Stephan J. Reskin)

**Metabolic reprogramming in cancer cells, consequences on pH and tumour progression:  
Integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer  
treatment**

Jean-François Dumas<sup>1,2</sup>, Lucie Brisson<sup>1</sup>, Stéphan Chevalier<sup>1,2</sup>, Karine Mahéo<sup>1,2</sup>, Gaëlle Fromont<sup>1,3</sup>, Driffa Moussata<sup>1,4</sup>, Pierre Besson<sup>1,2</sup> & Sébastien Roger<sup>1,5,6 #</sup>

1, Inserm UMR1069 Nutrition, Croissance et Cancer ; Université François-Rabelais de Tours,  
10 Boulevard Tonnellé, 37032 Tours, France

2, UFR Sciences Pharmaceutiques ; Université François-Rabelais de Tours, Avenue Monge,  
37200 Tours, France

3, Service d'anatomie et cytologie pathologiques, CHU de Tours, 37044 Tours cedex 9,  
France

4, Service d'hépatogastroentérologie et de cancérologie digestive, CHU de Tours, 37044  
Tours cedex 9, France

5, Département de Physiologie Animale, UFR Sciences et Techniques; Université François-  
Rabelais de Tours, Avenue Monge, 37200 Tours, France

6, Institut Universitaire de France, 1 rue Descartes, 75231 Paris, France

#, Corresponding author: Dr. Sébastien Roger,

UMR Inserm 1069, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours,  
France; Phone: (+33) 2 47 36 61 30; Fax: (+33) 2 47 36 62 26; Email: [sebastien.roger@univ-tours.fr](mailto:sebastien.roger@univ-tours.fr)

## **Abstract**

While tumours arise from acquired mutations in oncogenes or tumour-suppressor genes, it is now clearly established that cancers are metabolic diseases, characterized by metabolic alterations in both tumour cells and non-tumour cells of the host organism (resulting in tumour cachexia and patients weakness). This review aims at delineating details by which metabolic alterations in cancer cells, characterized by mitochondrial bioenergetics deregulations and the preference for aerobic glycolysis, are critical parameters controlling the aggressive progression of tumours. In particular, metabolic alteration in cancer cells are coupled to the modulation of intracellular and extracellular pH, epithelial-to-mesenchymal transition and associated increased invasiveness, autophagy and the development of anticancer treatment resistance. Finally, based on mechanistic, pre-clinical and clinical studies, we wish to propose the adjuvant supplementation of dietary n-3 polyunsaturated fatty acids for a complementary global treatment of the cancer disease.

### **Key words (5):**

Cancer cell metabolism, pH, cancer cell invasiveness, resistance to treatments, n-3 polyunsaturated fatty acids

**Abbreviations:**

**$\alpha$ -SMA:**  $\alpha$ -smooth muscle actin; AMPK : AMP-activated protein kinase; bHLH : basic Helix-Loop-Helix; DHA : docosahexaenoic acid (22:6n-3); Drp1 : dynamin-related protein 1 ; ECM : extracellular matrix ; EMT : epithelial-to-mesenchymal transition ; EPA: eicosapentaenoic acid (20:5n-6); ERK1/2: extracellular signal-regulated kinase ; <sup>18</sup>FdG: 18-fluorodeoxyglucose; HIF : Hypoxia-Inducible Factor ; IFP : interstitial fluid pressure; LDH: lactate dehydrogenase; MAPK : mitogen-activated protein kinase; mCAT: mitochondrial catalase; MCT : monocarboxylate-H<sup>+</sup> co-transporter; MDR : multidrug resistance ; MMP : matrix metalloproteinases; n-3 PUFA: n-3 polyunsaturated fatty acid; Na<sub>v</sub>: voltage-gated sodium channels; NHE : sodium-proton exchanger; NMU : N-nitroso-N-methylurea; OXPHOS : oxidative phosphorylation; PDH: pyruvate dehydrogenase; PET: positron emission tomography; P-gp: P-glycoprotein; PPAR : peroxisome proliferator activated receptor; PPI : proton pump inhibitor ; ROS : reactive oxygen species; TCA: tricarboxylic acid cycle; TMZ : temozolomide; UCP-2: mitochondrial uncoupling protein 2

## 1. Introduction

Cancer is a leading cause of death, and in 2012, it was estimated that 14.1 million new cancer cases and 8.2 million cancer deaths occurred in the world (1). These numbers are expected to increase rapidly in the next few years because of the growth and aging of populations, the changes in lifestyle and dietary behaviours, and/or the exposure to environmental conditions that are known or supposed to increase cancer risk. Cancer is often reduced as being a genetic disease. Indeed, the tumour mainly takes its origin in the occurrence of sporadic mutations leading to the amplification, or activation, of oncogenes (such as *SRC*, *AKT*) (2,3), the increased expression (or gain-of-function mutations) of proto-oncogenes (such a *RAS*, *MYC*, *WNT*) (4-6), or the acquisition of loss-of-function mutations in tumour-suppressor genes (such a *RBI*, *TP53*, *PTEN*, *APC*) (7-9). A small proportion of cancers, 5 to 15% of cases depending on cancer types, are hereditary due to the transmission of germline mutations in tumour-suppressor genes, such as the breast-ovarian hereditary cancers associated with mutations in *BRCA1/2* genes encoding for DNA repair enzymes (10).

These initial mutations, along with the stochastic accumulation of multiple others, lead to the selection of some cancer cell clones, generating a heterogeneous primary tumour, characterised by six minimal parameters identified as being the hallmarks of cancer: a sustained signalling promoting proliferation, a replicative immortality, the independence towards growth suppressors, the resistance to cell death, the induction of tumour angiogenesis, and the activation of invasive and pro-metastatic properties (11).

*Cancer progression*

The growth of this primary tumour, and its progression towards an aggressive phenotype result from mutual interactions between cancer cells and their microenvironment in the host organism. This microenvironment comprises stromal, endothelial and immune cells, extracellular matrices, and also soluble factors, such as cytokines, growth factors, and can be submitted to fluctuations in ionic composition, nutrients availability and oxygen tension. At the cellular level, the acquisition of extensive migration and extracellular matrix invasion potencies by cancer cells are critical steps in cancer progression, in the metastatic cascade (12,13) and eventually in patient death (14). Over the last decade, important knowledge on cancer cell migration and invasiveness has emerged, leading to the classification of different types of migrations, individual *versus* collective, and different migrating cell phenotypes, mesenchymal *versus* amoeboid (15,16). These specific phenotypes are not absolutely strict, but versatile as a function of changes in the microenvironment. It is generally accepted, that the acquisition of pro-invasive capacities is associated with the epithelial-to-mesenchymal transition (EMT), which is a reversible phenotypical and functional programme, reminiscent of physiological mechanisms involved in embryonic development or tissue repairing (17). During the EMT, cancer cells of epithelial origin dedifferentiate, they lose their apico-basal polarity to the profit of a rear-to-front cell polarity, lose intercellular junctions (especially tight and adherens junctions), remodel their intracellular cytoskeleton and gain mobility and resistance to apoptosis (Figure 1). They also overexpress and secrete ECM-degrading proteases, and express mesenchymal markers (vimentin, N-cadherin,  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), *etc.*) (18). The EMT is proposed to favour the acquisition of stemness characteristics in cancer cells (19,20), to support their survival in the bloodstream and their extravasation in metastatic sites (21,22). Increasing evidence suggests that the EMT, and the reverse process called mesenchymal-to-epithelial transition (MET), may be better described

as a spectrum of intermediate states that might depend on the physical and chemical nature of the microenvironment. The initiation of the EMT programme is driven by several signalling pathways including those mediated by transforming growth factor  $\beta$  (TGF- $\beta$ ) (23), bone morphogenetic protein (BMP) (24) or integrin signalling (25), that stimulate EMT-inducing transcription factors (Snail1/2, Zeb1/2, Twist) which bind to the promoter region of critical genes such as those regulating cell-cell adhesions (26-29). In a primary tumour, the induction of EMT is generally visualized in areas of hypoxia (30). In fact, low oxygen tension induces transcriptional, metabolic and phenotypic changes that directly induce, or synergize with signalling pathways inducing EMT (see paragraph 2.1 – “Aerobic glycolysis, pH regulation and consequences on cancer cell invasiveness and resistance to treatments”), thus linking this phenotypical switch to metabolic parameters. In the mesenchymal mode of invasion, cancer cells harbour an elongated fibroblast-like morphology, with a rear-to-front lamellopodial cell polarity. Their motility is dependent on the interaction of integrins, at focal sites, with components of the substratum. In this mode of invasion, cancer cells self-generate a path through the participation of invadosomal structures that perform the proteolytic remodelling of the ECM by both membrane-associated and extracellularly-released soluble proteases, such as MMP2, MMP9 or cysteine cathepsins, which extracellular release and activation are promoted by extracellular acidification (31-34). In the “amoeboid” mode of invasion, cancer cells generally present a rounded morphology, but their shape changes in order to move into small gaps of the ECM, with no need to degrade it, and they display a high speed of migration due to strong actomyosin contractions (35). While different cancer cell types may preferentially engage into one mode or the other, the most aggressive cancer cells show high plasticity, with transitions called MAT, for mesenchymal-to-amoeboid transition, or AMT for amoeboid-to-mesenchymal transition (35). These transitions, orchestrated by RhoGTPases

family members (such as Rac1/2, RhoA/B, cdc42) (36-38), offer selective advantages and compensatory mechanisms to invading cancer cells, by counteracting and adapting to changes in the microenvironment (matrix composition and stiffness, accessibility to oxygen and nutrients), and are also proposed to abrogate the efficacy of some anticancer treatments (39-41). Recently, some reports describe a very aggressive hybrid mesenchymal-amoeboid phenotype in some cancer cell types (42,43). The selection of drug resistant cancer cells is another critical step in the progression of the disease leading to a decrease in the efficacy of chemotherapies. The multidrug resistance (MDR) phenotype is the result of a multicomponent process, among which is the over-expression of ATP-binding cassettes (ABC) transporters, such as the P-glycoprotein (P-gp, also known as *ABCB1* or *MDR1*), which are highly energy-demanding for their activity of anticancer drug efflux. Drug resistance is also characterized by the capacity of cancer cells to counteract the oxidative stress generated by some chemotherapeutic agents, through a modulated Redox status, or to resist to apoptotic inducers. Recent studies suggest that EMT is importantly involved in the selection of chemotherapy-resistant cancer cells (44,45).

### *Cancer as a metabolic disease*

Cancer progression relies on bioenergetics parameters (46), and the metabolic reprogramming of cancer cells was added to the initial hallmarks of cancer (47). This reprogramming of the entire metabolism has consequences on protons dynamics in all cellular compartments (mitochondria, cytosol, lysosomes and autophagolysosomes), and extracellular compartments leading to a deregulated pH homeostasis, which, in adapted cancer cells, offers supplementary aggressive features to create a “perfect storm for cancer progression” (48). While the metabolic reprogramming is a general feature of tumours, it is not static and not



similarly applicable to all tumour cells. Furthermore, the nature of the metabolic reprogramming is highly dynamic, and might differ as a function of time and conditions (such as episodic deprivations of oxygen and nutrients, distance from blood vessels, stimulation by paracrine factors), as a function of cell types (cancer cells, cancer-associated fibroblasts, tumour-associated macrophages, endothelial cells, ...) and populations (cancer cell clones). Therefore, the metabolic reprogramming should not only be considered as a simple and permanent state in a cancer cell, but should rather take into consideration tumour spatio-temporal heterogeneity (49). These versatile metabolic adaptations not only allow cancer cells to survive to the pressure of environmental conditions by providing energy demand required to support the maintenance of their high anabolic activity for uncontrolled proliferation, but also exacerbate their migrative, invasive activities and metastatic properties (50,51).

It should be mentioned that metabolic reprogramming does not solely concern cancer and non-cancer cells from the tumour (metabolic interplay between cancer and non-cancer cells from the tumour, and also between oxygenated and hypoxic tumour cells), but also operates, most probably through the participation of an inflammatory component, in distant non-cancer tissues from the host organism, such as in liver, adipose tissue and skeletal muscles, leading to an overall deregulation of the energetic balance (52-54). A severe state of tumour-induced metabolic reprogramming, known as cancer cachexia, is a complex syndrome characterized by the loss of adipose and muscle mass, anorexia, and a general weakening of patients, impeding their quality of life and preventing the application of an effective anti-cancer treatment (55,56).

Therefore, it is proposed that the cancer disease, considering not only the tumour and its aggressive progression but also the response of the host organism to the presence of a tumour, is a metabolic disease. This review, focused on cancer cells, is intended to highlight how

cancer cell metabolic reprogramming couples with completely deregulated protons homeostasis and dynamics, promoting some aspects of cancer cell aggressiveness and tumour progression, such as the gain in invasive potential, the development of metastases and the resistance to anticancer treatments.

## **2. Metabolic switches in cancer cells and consequences on cancer cell properties**

Cancer cells in a tumour are selected under stringent environmental conditions of low oxygen levels, nutrients deprivation, acidic extracellular pH (pHe), exposure to anticancer treatments, and on their ability to fulfil intensive energetics needs required for their high proliferative, invasive and detoxifying activities. Under these stringent conditions, only cancer cells with an adaptative metabolism can survive, leading to the self-selection of the most aggressive cells.

### **2.1 - Hypoxia and the selection of cancer cells with high glycolytic activity**

In rapidly growing primary tumours, areas located away from blood capillaries (distance generally estimated as being  $> 150 \mu\text{m}$ ) reach the limit of oxygen diffusion and cancers cells in these regions are under temporary or sustained hypoxic conditions (57,58). The majority of cells, mostly relying on the oxygen-dependent mitochondrial oxidative phosphorylation (OXPHOS) to generate ATP, die in these conditions, in turn generating necrotic cores of tumours. In this scenario, only cells that are be able to cope with hypoxic conditions because of their metabolic preference for glycolysis, will survive. The principal cellular mechanism for the biological adaptation in response to hypoxia is the stabilisation of the Hypoxia-Inducible Factor (HIF), a transcription factor belonging to the basic Helix-Loop-Helix (bHLH) family. The HIF-1 is a heterodimeric factor composed of a stable HIF-1 $\beta$  subunit and

an unstable HIF-1 $\alpha$  subunit, the half-life of which is controlled by the level of oxygen. Indeed, in normoxic conditions, HIF-1 $\alpha$  is degraded by the successive action of oxygen-dependent prolyl hydroxylases (PHD) and Von Hippel-Lindau (VHL) ubiquitin ligases, while it is maintained under hypoxia (59). Stabilized HIF-1 factor inhibits mitochondrial biogenesis (60) and functionally cooperates with the MYC oncogene to promote the glycolytic metabolism (61). This includes the up-regulation of glucose transporters, particularly studied is the isoform 1 (GLUT1, gene *SLC2A1*), which allows an increase in glucose uptake, and the expression of glycolytic enzymes, such as hexokinases 1 and 2 (*HK1* and *HK2*), which are the primary enzymes needed for the entry of glucose in glycolysis, aldolase A (*ALDA*), which catalyses the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate, phosphoglycerate kinase 1 (*PGKI*), which catalyses the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP producing 3-phosphoglycerate, pyruvate kinase (PK), which catalyses the transfer of a phosphate group from phosphoenolpyruvate to ADP, thus giving one pyruvate and one ATP, and lactate dehydrogenase A (LDHA), which catalyses the inter-conversion of pyruvate and L-lactate with concomitant inter-conversion of NADH,H<sup>+</sup> and NAD<sup>+</sup> (62-64). An increasing number of studies also reports that hypoxia promotes the EMT in cancer cells (18). This can be mediated, not exclusively, through the HIF-1 $\alpha$ -dependent induction of EMT-promoting genes such as TGF- $\beta$  (100), ZEB2 (101), TWIST (102), and the loss of E-cadherin (103).

The resistance to hypoxia is therefore an important parameter leading to the selection of adapted cancer cells, and initial studies led to the observation that aggressive cancer cells display a highly increased glycolytic activity. Quite surprisingly, this metabolic pathway, in selected cancer cells, is still observed under normoxic conditions. This is contradictory to the “Pasteur effect”, generally observed in normal cells, characterizing the fact that the presence

of oxygen results in the activation of OXPHOS and the relative inhibition of glycolysis, since OXPHOS is 18 times more efficient than glycolysis in generating ATP from one molecule of glucose. This particular metabolism was called “aerobic glycolysis”, which might be confusing since glycolysis does not require oxygen. This is also often referred as being the “Warburg effect” (65,66). Since the initial description by Otto Warburg, the “aerobic glycolysis” was demonstrated in different cancer types (67) and the study of tumour metabolism became an important research field, for both basic and translational research. For example, the detection and imaging of tumours, displaying a high consumption of glucose, can be performed with the analogue <sup>18</sup>fluorodeoxyglucose (<sup>18</sup>FdG) as a tracer in positron-emission tomography (PET) (68,69). While “aerobic glycolysis” might be a general mechanism associated with cancer progression, the hypothesis proposed by Otto Warburg that this might be the consequence of a defective mitochondrial activity (70) was not verified, and it is known that mitochondria are fully functional in cancer cells and contribute to cancer progression (51). In this context, it is proposed that the aerobic glycolysis is a supplementary and regulatory metabolic pathway fulfilling the high energy demand of cancer cells.

It should be stated that within a tumour, there is a metabolic cooperation between cancer and non-cancer cells. As such, the understanding for a tumour metabolism with metabolic coupling between cancer cells and stromal cells from the tumour had been previously proposed by Lisanti and collaborators and was termed “The reverse Warburg effect” (71). In the tumour, cancer cells generate oxidative stress in neighbouring stromal fibroblasts or mesenchymal stem cells, thus leading to the onset of “aerobic glycolysis” in those non-cancer cells. In turn, the excess of lactate and pyruvate, the energy metabolites resulting from aerobic glycolysis from non-cancer cells, is transferred to adjacent cancer cells where they enter in the

tricarboxylic acid cycle (TCA), resulting in increased OXPHOS and efficient ATP production (71,72).

A metabolic cooperation has also been identified between cancer cells themselves and between cancer cells and non-cancer cells from the tumour microenvironment. In the case of ovarian cancers, adipocytes provide free fatty acids to cancer cells, after the hydrolysis of triacylglycerids (lipolysis) to fuel mitochondrial  $\beta$ -oxidation and promote tumour growth (73). In addition, a metabolic symbiosis between glycolytic and oxidative cancer cells was demonstrated through the exchange of lactate. In this model, lactate produced and excreted by glycolytic cancer cells, whether being in hypoxic conditions or not, is transported through monocarboxylate- $H^+$  co-transporters (MCT) in oxidative cancer cells. These later use LDHB to convert lactate into pyruvate and fuel the TCA cycle and promote tumour growth (74,75).

## **2.2 - Roles of mitochondrial bioenergetics in cancer progression**

### *- Mitochondrial activity, cancer cell invasiveness and metastases -*

Cancer cell migration and invasiveness are two critical aspects of the metastatic potential that may require a boost in energy and in this scenario, mitochondrial energy metabolism would be important. Therefore, several studies suggest that the regulation of the mitochondrial metabolic activity is an important determinant of the metastatic process. This has been elegantly shown *in vivo* by Tan and collaborators (76). In this study, the intravenous injection of tumour cells bearing no mitochondrial DNA (mtDNA), and therefore showing compromised mitochondrial energy metabolism, presented a delayed tumour growth in mice. Interestingly, metastatic cells were deriving from mtDNA-deficient carcinoma cells that obtained mtDNA from host murine cells, and exhibited full restoration of mitochondrial energy metabolism. These data indicate that “horizontal transfer” of mitochondria from host

cells to cancer cells in the tumour microenvironment play a role in metastases (76). Moreover, it has been shown that migratory/invasive cancer cells specifically favour mitochondrial oxygen consumption and have an increased ATP production (77). Invasive cancer cells use the transcription co-activator peroxisome proliferator-activated receptor gamma, co-activator 1 alpha (*PPARGC1A*, also known as PGC-1 $\alpha$ ) to enhance mitochondrial biogenesis and mitochondrial OXPHOS. Silencing of PGC-1 $\alpha$  in cancer cells inhibited their invasive potential and attenuated metastasis (77). Correlatively, the increased expression of genes known to be involved in the mitochondrial energy metabolism, accompanied by a gain in mitochondrial biogenesis, was also observed in breast cancer cells originating from brain metastases (78). It has been shown that mitochondrial complex I activity was critical in defining the metastatic phenotype of breast cancer cells (79). Thus enhancing complex I activity inhibited metastasis, partly through the regulation of the tumour cell NAD<sup>+</sup>/NADH,H<sup>+</sup> redox balance (79).

Mitochondria are high dynamic organelles with frequent fission and fusion that impact mitochondrial and cellular activities. It has been reported that hypoxia stimulated mitochondrial fusion and migration in metastatic breast cancer MDA-MB 231 cells, by increasing the expression of dynamin-related protein 1 (Drp1) (80). Moreover, inhibition of Drp1-dependent mitochondrial fission by Mdivi-1, an inhibitor of fission, or silencing Drp1 attenuated hypoxia-induced migration in MDA-MB 231 cells (80). Furthermore, it has been shown that EGF induced the translocation of its receptor EGFR to mitochondria that in turn induced mitochondrial fission, cellular redistribution of mitochondria to the lamellipodia, upregulated cellular ATP production, and enhanced cancer cell motility both *in vitro* and *in vivo* (81). In addition, the overexpression of Mitofusin 1, an actor of mitochondrial fusion, significantly alleviated the mitochondrial EGFR-mediated higher ATP production and cell

migration (81). Therefore, one could consider that the inhibition of mitochondrial fusion may be an important mechanism to prevent metastasis.

Mitochondria are major sites of **reactive oxygen species (ROS) production**, mostly occurring during the process of electron transfer through mitochondrial electron-transport chain enzymes at complex I and complex III (82,83). It has been shown that ROS induced by mitochondrial dysfunction enhances gastric cancer metastasis (84). By replacing the endogenous mtDNA of a poorly metastatic mouse tumour cell line, by the mtDNA derived from a highly metastatic mouse tumour cell line (cytoplasmic hybrid (cybrid) technology), it has been shown, both *in vitro* and *in vivo*, that mutations in mtDNA can enhance the metastatic potential of tumour cells by inducing defects in complex I, thus resulting in the increase of mitochondrial ROS production (85). Additional evidence implicating the role of the oxidative stress generated by mitochondrial activity in cancer metastasis comes from the study of Goh and colleagues (86). In their study, transgenic mice expressing a human mitochondrial catalase (mCAT) were crossed with MMTV-PyMT transgenic mice that spontaneously develop metastatic mammary cancer. Data showed that PyMT mice expressing mCAT had a lower incidence of metastasis compared to controlled PyMT mice not expressing mCAT. Moreover, PyMT tumour cells expressing mCAT had lower mitochondrial ROS levels than wild type tumour cells (86). A critical role for mitochondrial ROS in metastasis has also been reported by Porporato and collaborators (87). Indeed, they demonstrated that cancer cell migration, invasiveness and spontaneous metastasis in mice were promoted by the natural selection of two mitochondrial phenotypes leading to an enhanced mitochondrial ROS production: *i.e.* overload of the mitochondrial electron transport chain *vs.* partial mitochondrial electron transport chain inhibition. In addition, in this study, the specific scavenging of mitochondrial ROS with MitoTEMPO blocked tumour cell migration and

prevented spontaneous metastasis in both murine and human tumour models (87). In contrast, it has been shown that metastatic cancer cells can release mitochondrial ROS, induce oxidative stress and aerobic glycolysis in the non-cancer cells of the tumour microenvironment, which in turn generate L-lactate and ketone bodies that fuel mitochondrial energy metabolism in cancer cells, as a part of the reverse Warburg effect (88-90).

#### *-Mitochondrial activity in the resistance to anticancer treatments-*

Several studies have focused on the role of mitochondria and intracellular ATP in the development of anticancer drug resistance by cancer cells. For instance, this has been shown in CD44<sup>+</sup>/MyD88<sup>+</sup> ovarian cancer stem cells that are resistant to apoptotic cell death induced by conventional chemotherapy agents. Indeed, in these extremely chemoresistant cells, the isoflavone derivative, NV-128, significantly depressed the mitochondrial function, as confirmed by a decrease in ATP synthesis, and by the increase in mitochondrial superoxide and hydrogen peroxide, and in turn activated cell death (91). On one hand, by comparing oxaliplatin-sensitive to –resistant cancer cells, it has been demonstrated that exogenous ATP delivery to sensitive cells partially blocked the cytotoxic effect of oxaliplatin (92). On the other hand, ATP depletion in resistant cells partially re-sensitized resistant cell lines to oxaliplatin, indicating the prominent role of intracellular ATP level in mediating the drug-resistant phenotype (92). Differently, by comparing several 5-fluorouracil (5-FU)-sensitive to –resistant colon cancer cells, the authors reported a down-regulation of mitochondrial ATP synthase subunits, a lower mitochondrial ATP synthase activity and a decreased intracellular ATP content in chemoresistant cells compared with parent cells (93). In addition to this, it was found that 5-FU sensitivity positively correlated with mitochondrial ATP synthase expression and activity. Finally, knocking-down the mitochondrial ATP synthase expression,



by using siRNA, induced a higher viability of sensitive cells under the treatment with different concentrations of 5-FU (93). One obstacle of chemotherapy efficacy is the overexpression of a superfamily of energy-dependent ATP binding cassette transporters that extrude anticancer drugs out of the cell. It has been suggested that the modulation of mitochondrial energy metabolism could reduce drug resistance by restoring the capacity to accumulate and retain drug in the cells. Thus, it has been showed that oligomycin could suppress the activity of the P-gp expressed at the plasma membrane, at an extent similar to the P-gp inhibitor verapamil, and increased accumulation of doxorubicin in doxorubicin-resistant HepG2 cells (94). Although ATP-dependent efflux pumps are generally considered to be localized at the plasma **membrane**, it has been showed that BCRP (breast cancer resistant protein), MRP1 (multidrug resistance protein 1) or P-gp could also be expressed in mitochondria from leukaemia, ovarian carcinoma, sarcoma and hepatocellular doxorubicin-resistant cancer cells (95-98). It has been described that BCRP and MRP1 pumps, expressed in the mitochondrial membrane, maintain the direction of transport similarly to that in the plasma membrane (inside towards outside). Therefore, it is proposed that mitochondrial ATP-dependent efflux pumps could be involved in the protection of mitochondria from damage due to anticancer drugs (Figure 2). Since functionally active mitochondrial pumps require ATP for their efflux activity, one could argue that mitochondrial energy production in chemoresistant cells participates to the ATP used for the functioning of mitochondrial efflux pumps.

It has been suggested that the toxicity level of drugs towards cancer cells was dependent on the mitochondrial mass. For example, the introduction of normal mitochondria from immortalized, untransformed MCF-12A cells in breast cancer cells MCF-7 increased their sensitivity to doxorubicin, abraxane, and carboplatin (99). In this context, it has been shown that the treatment of breast cancer cells with the thyroid hormone (T3) increased

mitochondrial mass, modulated the bioenergetics profile and enhanced doxorubicin-induced cell death (100). Such a link between mitochondrial mass and chemoresistance has also been found in oxygen-deficient conditions. Thus, it has been observed, in lung cancer cell lines, that hypoxia-induced resistance to cisplatin and doxorubicin were associated with a decrease in number and size of mitochondria (101).

Several studies have used dichloroacetate, a pyruvate dehydrogenase kinase inhibitor that activates mitochondrial OXPHOS, to target metabolism in cancer cells. Using this methodology, it has been suggested that the activation of mitochondrial OXPHOS was more effective than the suppression of glycolysis in overcoming sorafenib resistance in highly glycolytic hepatocellular carcinoma (HCC) cells (102). Indeed, although enhanced glycolysis was positively correlated with sorafenib resistance of HCC cells, dichloroacetate, by activating mitochondrial OXPHOS, markedly sensitised sorafenib-resistant cells to sorafenib-induced apoptosis. By contrast, the inhibition of glycolysis, by silencing the expression of hexokinase 2, was ineffective (102). In addition, it has been shown that combination of dichloroacetate and cisplatin exhibited a significant synergistic activity in reducing the viability of HeLa cells (103). Furthermore, it has been shown that the use of dichloroacetate, in combination with doxorubicin or cisplatin, reduced the cytotoxicity of these two drugs *in vitro*, on a range of human cancer cell lines (104). Even if the precise mechanisms still need to be clarified, these studies suggest that mitochondrial energy metabolism is involved in the chemoresistance of cancer cells and tumours (Figure 2).

Multiple anticancer drugs induce cell death through the generation of ROS, and even agents that have been characterized to generate cancer cell apoptosis through the interaction with DNA (such as cisplatin, bleomycin, doxorubicin, methotrexate, busulfan and fluorouracil) are known to generate mitochondrial ROS (105). The role of mitochondria in the interplay

between ROS production and chemoresistance has been studied by Alakhova and collaborators (106). In their study, they showed that part of the sensitizing effects of pluronic, a synthetic amphiphilic copolymer, in multidrug resistant cancer cells was associated with an increased production of mitochondrial ROS and the release of cytochrome c, induced by the impairment of the mitochondrial oxygen consumption (106). To test the hypothesis that chemoresistance arises from decreased production of ROS, mitochondrial function has been assessed in temozolomide (TMZ)-sensitive (U251) or -resistant (UTMZ) glioma cells and in TMZ-resistant glioblastoma xenografts (107). Firstly, data showed that mitochondrial coupling (an indicator of ATP synthesis efficiency) was higher, and consequently mitochondrial ROS production was significantly lower, in TMZ-resistant cells. Secondly, it has been found that mitochondrial DNA-depleted cells (U251 $\rho$ 0), a model of non-functional mitochondria, became resistant to TMZ and had lower intracellular ROS levels after TMZ exposure compared with parental sensitive cells. Finally, restoration of  $\rho$ 0 cells with mitochondria restored ROS production and sensitivity to TMZ (107). Taken together, these data indicate that chemoresistance could be due to low mitochondrial ROS production. In another study, it has been showed that basal level of ROS production is lower or identical in chemoresistant cancer cells. However, radiations increased levels of ROS in drug-sensitive cells and not, or even a slight reduction, in drug-resistant cells (108). Interestingly, this phenomenon was associated to a higher expression of the mitochondrial uncoupling protein 2 (UCP2) in drug-resistant cancer cells, suggesting that mitochondrial ROS production was lower (108). Although the exact role of UCP2 needs to be determined, various studies have shown that it could prevent mitochondrial oxidative stress generation by increasing the flow of protons into the mitochondrial matrix (increased proton leak), thus rendering electron flow through the mitochondrial respiratory complexes more elevated (109-111). By using drug-

sensitive HL-60 human acute promyelocytic leukemia cells and the drug-resistant HL-60/MX2 cells as models, it has been showed that genipin, by inhibiting UCP2, sensitized drug-resistant cells to cytotoxic agents (menadione, doxorubicin, and epirubicin) and that sensitization of drug-resistant cells was accompanied by increased levels of cellular ROS (112). In addition, the drug-induced increase in mitochondrial ROS was linked to genipin-mediated inhibition of mitochondrial proton leak (112). Pons and collaborators have recently conducted a study in which ROS production and sensitivity to cisplatin or tamoxifen were tested in two breast cell lines (MCF-7 and T47D) as a function of UCP2 expression and function (using siRNA and genipin, respectively) (113). Data showed that inhibition of UCP2 improved the efficacy of each drug to decrease cell viability, and increased the production of mitochondrial ROS in both cell lines (113). Similarly, a role for mitochondrial oxidative stress in chemoresistance was also identified in the case of the anticancer drug gemcitabine (GEM). It has been demonstrated that mitochondrial uncoupling, induced by the chemical uncoupler carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP), or by the over-expression of UCP2, strongly decreased GEM-induced mitochondrial ROS and protected cancer cells (pancreatic adenocarcinoma, non-small cell lung adenocarcinoma and bladder carcinoma) to GEM-induced apoptosis (114). In addition, GEM treatment and UCP2 inhibition (by genipin) strongly induced mitochondrial superoxide production and ROS-mediated apoptosis in cancer cells (114). A role for mitochondrial ROS in chemoresistance has also been demonstrated by Okon and collaborators (115). However, in this study, ROS levels were higher and catalase (antioxidant enzyme) levels were lower in gefitinib (a tyrosine kinase inhibitor)-resistant lung H1650G adenocarcinoma cell line than in the sensitive H1650 counterpart. This stress oxidative phenotype was associated with a lower mitochondrial oxygen consumption. In addition, when H1650 cells were grown over several weeks in the

presence of gefitinib (as carried out to generate gefitinib-resistant H1650 Clones) and the mitochondria-specific ROS scavenger MitoTEMPO, mitochondrial oxygen consumption was not decreased and ROS levels were not increased (115). This demonstrated a direct link between mitochondrial ROS production, mitochondrial dysfunction and resistance to gefitinib.

Interestingly, recent studies pointed out the role of mitochondrial dynamics in chemoresistance. Thus, it was showed that piceatannol, a natural metabolite of the stilbene resveratrol, was a potent enhancer of cisplatin sensitivity in different human ovarian cancer cell lines (sensitive or not to the drug) (116). Interestingly, this effect was associated, among other things, with an increase in mitochondrial fission. Indeed, the number of cells showing signs of apoptosis and fragmented mitochondria were increased by the co-treatment of piceatannol with cisplatin, while they were lower when mDivi-1, an inhibitor of fission, was added (116). Differently, the study conducted by Santin and collaborators suggested that the increased fusion of mitochondria, to the detriment of fission, may be the mechanism responsible for drug resistance. In B50 neuroblastoma rat cells, an expected apoptosis was induced after a 48h-long exposure to cisplatin, but under a long-term exposure to the drug, the elongation of mitochondria was associated with a reduction of the apoptosis rate (117).

### **2.3. pH regulation as a consequence of metabolic reprogramming, effect on cancer progression and resistance to anticancer treatments**

One consequence of this complete metabolic reprogramming, and high activity is the increased production of acid equivalents that are exported in the extracellular space leading to an acidic pH<sub>e</sub> (Figure 2). While there might be some metabolic heterogeneity within the tumour (118), there is a good correlation between glucose consumption in tumours, as

monitored by PET using  $^{18}\text{F}$ dG-Glucose uptake, and acidic regions as monitored using pH-sensitive fluorescent probes or Magnetic Resonance Imaging (119,120). This would involve the glycolytic metabolism in the production of protons. However, the production of lactate from glucose, by the glycolysis does not produce any proton. Therefore, the majority of the production of acid equivalents associated with the glycolytic activity might be produced at the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) step, or even consecutive to the correlative high energetic demand, leading to the hydrolysis of ATP to ADP. While some authors argue for the dissociation of lactic acid into lactate and  $\text{H}^+$  (pKa 3.9), the conversion reaction of pyruvate into lactate by the LDHA consumes protons. Because LDHA- and glycolysis-deficient tumours are still producing extracellular acidification, it is proposed that the glycolysis is not the only source of  $\text{H}^+$  in cancer cells (121-123). Additional sources of protons could come from the  $\text{CO}_2$  produced during the pentose phosphate pathway in the cytosol and the tricarboxylic acid (TCA) cycle in mitochondria (Figure 2).

In any case, excessively produced  $\text{H}^+$  are extruded in order to maintain the intracellular pH (pHi) and permit cancer cells to survive (124-126). This is allowed by overexpression of proton-extruding plasma membrane transporters, such as the electroneutral  $\text{Na}^+/\text{H}^+$  exchanger type 1 (NHE1), MCT monocarboxylate- $\text{H}^+$  co-transporters (particularly the MCT-4 isoform, which is mediated by hypoxia through HIF-1 $\alpha$ ), bicarbonate transporters (such as the electroneutral or electrogenic  $\text{Na}^+/\text{HCO}_3^-$  co-transporters NBCs, electrogenic  $\text{Na}^+$ -dependent  $\text{Cl}^-/\text{HCO}_3^-$  exchangers NDCBE) and proton pumps (such as the electrogenic vacuolar-type  $\text{H}^+$ -ATPase V-ATPase), and for inducible transmembrane carbonic anhydrase isoforms 9 and 12 (CA-9 and CA-12) (127-129). *In vitro*, the expression and activity of these acid-extruding transporters were demonstrated to control the 3-dimensional growth of human breast cancer cells spheroids (130). These numerous plasma membrane proteins are essential for

maintaining pHi and their activities result in the decrease of pHe. It is interesting to point out that some of these are active transporters (ATPases) hydrolysing high amounts of ATP to export protons produced by the glycolytic energetic pathway, and allow cancer cell survival. This could appear as being an aberrant situation, if we did not consider the fact that this extrusion of H<sup>+</sup> in the extracellular space also provides selective advantages to cancer cells by conferring them with enhanced proliferative (131), migratory and invasive activities (32,132-134), while reducing the anticancer immune response (124,135).

While there might be some differences depending on the considered tissue, pHi is generally comprised between 6.9 and 7.2, and is slightly more acidic than pHe, which is comprised between 7.2 and 7.4 under physiological conditions (125,136). It is also noticeable that the activities of H<sup>+</sup> transporters and pumps cited above, not only maintain pHi to values compatible with cell survival, but further enhance the extrusion of protons, thus reversing the proton gradient in cancer cells with a pHi > 7.2 and a pHe < 7.0 (48). Far from being deleterious to cancer cells, this extracellular acidification in solid tumours (57) triggers the apoptotic cell death of non-cancer cells (137). In cancer cells, the acidic pHe further participates to genomic instability by reducing DNA repair and promoting the acquisition of further mutations (138).

#### *-pH regulation, cancer cell invasiveness and metastases -*

Among all pH regulators, **NHE1** was functionally associated with cancer cell survival, migration and metastatic progression (32,125). NHE1 uses the inwardly directed electrochemical Na<sup>+</sup> gradient to exchange H<sup>+</sup> for Na<sup>+</sup> ions with a stoichiometry of 1:1 (139). This plasma membrane exchanger is ubiquitously expressed. It is quiescent at physiological pHi ~7.2, but activates rapidly upon intracellular acidification (140) and is therefore involved

in the protection of normal cells upon intracellular acidification bursts (128) **while acidifying the extracellular environment**. Its activity is tightly regulated by multiple hormonal and mitogenic pathways (141). In cancer cells, NHE1 is both overexpressed and overactivated (142), and is involved in cancer cell motility and matrix degradation (33,143). The increased NHE1 expression and activity are considered to constitute an unfavourable prognostic factor, such as in the case of ovarian cancers (144).

NHE1 overexpression in cancer cells is also suggested to be a part of the EMT. Indeed, in prostate cancer cells, the expression of NHE1 is strongly correlated with the expression of Zeb1, a crucial transcription factor activating the mesenchymal gene expression program (145). Furthermore, Zeb1 was found to bind to the promoter of NHE1 gene (*SLC9A1*) and support its expression. NHE1 up-regulation was even proposed to drive carcinogenesis (142). **Importantly, it was demonstrated that low levels of intracellular ROS, which confer cells with resistance capacities to death stimuli, could up-regulate the expression of NHE1 during carcinogenesis (146).**

NHE1 was subsequently involved in the trafficking of lysosomes to the plasma membrane and the secretion of proteases involved in cancer cell invasion (145). Of interest is the recent publication from D. Lagadic-Gossmann's group showing that the genotoxic and carcinogenic agent, benzo[a]pyrene, a polycyclic aromatic hydrocarbon pollutant from exhaust fumes and cigarette smoke, found in food and drinking water, also promotes metabolic reprogramming in hepatic cancer cells and EMT through NHE1 regulation (147). Benzo[a]pyrene treatment was responsible for a reduction of mitochondrial respiration, and correlative increases in glucose oxidation, lactate release and extracellular acidification, which recapitulated a switch towards an aerobic glycolysis. These changes were prevented by the use of the NHE1 inhibitor cariporide (147).



NHE1 is known to support the ECM degradative activity that is associated with the mesenchymal phenotype. Indeed, it has a predominant role in extracellular acidification, the activity of invadopodia and in the invasiveness of cancer cells (33,125,134,148) (Figure 1). NHE1 has also been identified as a key regulator of oriented actin polymerisation for invadopodia initiation. This occurs both through scaffolding properties, as it interacts with actin-binding proteins of the ERM (ezrin, radixin and moesin) family, and through its activity, as the resulting intracellular alkalinisation allows the release of the actin-severing factor cofilin and disrupts its inhibitory interaction with cortactin (125,149,150). Furthermore, the activation of focal adhesion kinase (FAK), which is an important parameter of cancer cell migration and survival, was found to be sensitive to pHi. Alkaline pHi was demonstrated to induce FAK conformational changes allowing its autophosphorylation on tyrosine residue 397. This was prevented by **knocking-down NHE1 expression** and resulted in the impairment of focal adhesions and cell spreading (151).

It is worth noticing that, in cancer cells, not only the expression is increased, but most importantly the activity of NHE1 is enhanced, despite the relatively alkalinized pHi of cancer cells (125), a condition for which it would be inactive in normal cells. Signalling pathways that are often overactivated in cancer cells are also known to upregulate the activity of NHE1. This is the case for some growth factor (141), extracellular signal-regulated kinase (ERK1/2) (152,153), or B-Raf kinase (154) signalling pathways that would enhance the extrusion of H<sup>+</sup> through NHE1 activity in alkaline pHi. **Therefore it seems that several signalling pathways, such as mitogenic pathways, up-regulate the expression of several proton extruders, including NHE1, thus responsible for intracellular alkalinisation, but also sustain their activity in alkaline pHi.**

Further to the regulations previously mentioned, it was demonstrated that voltage-gated sodium channels ( $\text{Na}_v$ ), overexpressed in carcinoma cells (155-157), and known to participate to the mesenchymal invasion of cancer cells, further enhance NHE1 activity in cancer cells.  $\text{Na}_v$  channels were initially proposed to be characteristics of excitable cells, such as skeletal and cardiac muscle cells, while their expression is generally repressed in non-excitable cells, such as epithelial cells.  $\text{Na}_v$  activity, through a transient entry of sodium charges, leads to the depolarization of the membrane responsible for the initiation and propagation of action potentials (158-163). More recently,  $\text{Na}_v$  were found to be expressed in carcinoma, such as in prostate, breast, lung, colon, cervix, ovary cancers, while they are not expressed in non-cancer tissues (164). It was proposed that their expression and activity are associated with cancer progression (155,156,165), metastases development and patients' death (166,167). In highly aggressive human breast cancer cells, the activity of the  $\text{Na}_v1.5$  pore-forming subunit participated to the acquisition of a mesenchymal phenotype by controlling Src kinase activity and the phosphorylation of the actin-nucleation promoting factor cortactin (168). Furthermore,  $\text{Na}_v1.5$  enhanced extracellular matrix (ECM) degradation and cancer cell invasiveness in 2 and 3-dimension matrices, by increasing the activity of extracellular cysteine cathepsins B and S (168-170) which have a maximal activity in acidic conditions (171) (Figure 1). While the activity of  $\text{Na}_v$  is transient (generating rapidly-inactivating, inward currents),  $\text{Na}_v1.5$  was proposed to promote cancer cell invasiveness through a persistent window current at the membrane potential of cancer cells. This current, through a not yet described signalling pathway, was responsible for the allosteric activation of NHE1, rendering it more sensitive to intracellular  $\text{H}^+$ , thus increasing its  $\text{H}^+$  efflux activity and the activation of extracellular cathepsins (168,172). While it is demonstrated that  $\text{Na}_v1.5$  activity supports mesenchymal invasiveness of breast cancer cells, *i.e.* invasion that require ECM

proteolysis, the participation of  $\text{Na}_v$  channels to the EMT have not been fully characterized. A recent study from Nelson and collaborators indicated that the down-regulation of  $\text{Na}_v1.5$  expression, using specific shRNA, resulted in an increase in MDA-MB-231 cell circularity and favoured a more rounded epithelial-like phenotype (173), thus corroborating previous findings (168,174). However, this was not associated with any alteration in E-cadherin, N-cadherin, vimentin, slug or snail expression. In contrast, the protein level of CD44, known to promote invasiveness and metastasis of breast cancer cells, was significantly reduced (173).

Further supporting the critical role of  $\text{Na}_v$ -NHE1 complexes in cancer progression, the  $\text{Na}_v1.7$  pore-forming subunit was recently identified to promote gastric cancer cell invasiveness through the metastasis-associated in colon cancer-1 (MACC1)-dependent up-regulation of NHE1 (175).  $\text{Na}_v$  channels in cancer cells are critical for the metastatic colonization of organs, and their inhibitors that are clinically used for the treatment of other pathologies were demonstrated to be powerful pharmacological tools to inhibit cancer cell invasiveness and prevent metastatic colonization (166,174,176,177).

While NHE1 activity is electroneutral, some of the other pH regulators cited above are electrogenic and their activity might regulate the membrane potential ( $E_m$ ) of cancer cells at the same time they control  $\text{H}^+$  homeostasis, thus also controlling the activity of voltage-sensitive ion channels and/or the driving force for some ions. Furthermore, several ion channels are directly gated by extracellular  $\text{H}^+$ , such as acid-sensing ion channels (ASIC) (178), while some other are regulated by acidic pH such as TRPV1 (179,180) and TRPA1 (181,182). These ion channels have recently been proposed to be involved in cancer progression through the promotion of lymphatic metastasis (183), and to be responsible for pain associated with cancer (184-186).

The acidic pHe has also been demonstrated to participate to the acquisition, by cancer cells, of aggressive features that are characteristics of the EMT. Indeed, the acidic pHe induces the loss of  $\beta$ -catenin from adherens junction in hepatocarcinoma cells through the activation of Src kinase (187), and the degradation of E-cadherin (188). The acidic pHe also participate to the acquisition of a mesenchymal, fibroblast-like, elongated cell phenotype, that is involved in an increased migratory activity (133,189) and an ECM-degradative function that participate to the metastatic evasion/invasion of tissues (32). While some of these aspects may be associated with pH by itself, some others were directly correlated with the activity of specific pH regulators. The acidification of the tumour microenvironment, is implicated in a positive feedback loop further enhancing the mesenchymal phenotype and the degradation of the extracellular matrix. Zeb1 promotes the NHE1-dependent anterograde lysosome trafficking to the plasma membrane, supporting ECM degradation and invasion by cancer cells (145). With an acidic pHe, the number of lysosomes decreased, owing to their displacement to the cell periphery and their exocytosis. This was shown to increase the secretion of degradative enzymes, but also the formation of filopodial structures, which together contributed to cancer cell invasiveness (34). The acidic pHe also indirectly promotes EMT in cancer cells. In a recent study, it has been shown that mesenchymal stem cells grown in low pHe conditions favour the growth and progression of melanoma through a release of TGF- $\beta$  and the acquisition of an EMT program in melanoma cells (190).

Lastly, the acidic environment of tumours also controls the metabolic activity of cancer cells. In the tumour, cancer cells are exposed to intermittent hypoxic episodes between which oxygen becomes sufficient again to allow mitochondrial respiration, while the acidic microenvironment is maintained. This acidic microenvironment also interferes with the metabolism of oxygenated cancer cells, in proximity of blood vessels, in the tumour. The two

recent studies of Corbet and collaborators demonstrate that cancer cells **subjected** to an acidic environment (pH 6.5) have a preferred glutamine reductive metabolism (191), and fatty acid oxidation to provide acetyl-coA to the TCA cycle (192). The consequences of this rewiring of metabolism are the preferred consumption of fatty acids to provide energy, but also the reduction of **ROS** production due to the hyperacetylation of mitochondrial complex I, which together support cancer cell proliferation and tumour growth (192).

#### *-pH regulation and resistance to anticancer treatments-*

**Major mechanisms contributing to chemo-resistance are the down-regulation of cell death mechanisms, but also the limitation of anticancer drug diffusion mainly** due to the poor vascular perfusion of tumours, and the overexpression or activity of P-gp mediating the ATP-dependent efflux of drugs. The characteristics of tumour microenvironment, *i.e.* hypoxia, low nutrients concentration, high lactate concentration, and acidic **pHe**, which are consequences of the abnormal vascularization of tumours and the glycolytic metabolism of some tumour cells, are critical factors contributing to drug resistance.

The acidic **pHe** of the tumour microenvironment plays an important role in limiting drug diffusion. This particular phenomenon, called “ion trapping”, occurs when the plasma membrane permeability of a drug is different for its ionized or non-ionized form (193,194). The ratio of ionized *versus* non-ionized form of a drug is pH-dependent. At acidic pH, molecules that are weak bases are ionized into protonated, positively charged drugs with limited diffusion through the plasma membrane. Common chemotherapeutic drugs are weak bases such as anthracyclines, anthraquinones and vinca alkaloids. As such, both *in vitro* and *in vivo* studies evidenced that an acidic **pHe** prevents the distribution of these weak bases inside cancer cells, thus leading to a decreased efficacy in treatment (195-198) (Figure 2). On

the opposite, drugs that behave as weak acids are permeable in their non-ionized form at acidic pH, are deprotonated and become negatively charged when they reach the slightly alkaline intracellular milieu. Therefore, they are trapped intracellularly and gain in efficacy. This is the case of chlorambucil, cyclophosphamide (alkylating agents) and 5-FU (antimetabolic), which all have an enhanced uptake in acidic pHe conditions (197,199,200). As a result, the experimental acidification of the extra-tumoral pH *in vivo*, by -0.2 pH unit, using glucose administration, led to an increased efficiency of the weak acid chlorambucil, while it inhibited the tumour growth-reduction effect induced by the weak base doxorubicin (196). On the contrary, the cytotoxic action of the alkylating agent melphalan, which is indicated for advanced breast and ovarian cancer and myeloma, and which can be assimilated as an acid drug, is more effective at acidic pH under hypoxia (201,202). This consideration was taken into account for the treatment of confined advanced metastatic melanoma, by using the isolated limb infusion of melphalan under non-oxygenated conditions to reduce pHe (203). Taken together, these studies clearly highlight the contribution of tumour metabolism to produce acidity and its relevance to cancer treatment.

In addition, this dysregulation of the pH homeostasis occurring in cancer cells influences drug distribution within the different intracellular compartments. Weak base anticancer drugs in the intracellular medium can be sequestered in acidic organelles (lysosomes, endosomes), thus limiting their availability to exert cytotoxic effects. Osteosarcoma cells exposed to an pHe of 6.5, have been shown to present a higher population of lysosomes being more acidic, and this was associated with a reduction in the cytotoxic effect of the anthracyclin doxorubicin, because of a reduced nuclear localization (198). This intracellular trapping of anticancer drugs is exacerbated in multidrug resistant breast cancer cells since they have more acidic

endosomes and lysosomes compared to sensitive cells. As a result, this provokes an accumulation of basic drugs in these acidic compartments and a reduced cytotoxicity (204).

Recent studies report that the reduced efficacy of anticancer drugs in acidic pH is also related with P-gp-dependent efflux. While the expression of the P-gp does not seem to be modified under acidic environment, its drug efflux activity is enhanced (205,206) (Figure 2). It was proposed by the authors that the acute exposure to an acidic **pHe** (6.6) induces a reduction of intracellular  $\text{Ca}^{2+}$  concentration, which increases the transport rate of P-gp. While the molecular details of the control of the intracellular  $\text{Ca}^{2+}$  homeostasis was not described, a comparable effect was found with the inhibition of protein kinase C (PKC). This effect was potentiated by hypoxia, which is a critical parameter of the tumour microenvironment (205,206). Furthermore it has been proposed that alterations of cell membrane mechanical properties induced by **pHi** in cancer cells may also participate to the control of doxorubicin diffusion inside the cells and to the acquisition of the resistance phenotype (207).

Therefore, the reverse pH gradient that is characteristic of tumours has important consequences for the efficacy of the anticancer treatment, and development of resistant tumours. This reality should be taken into account for the development of more effective anticancer treatments, leading to new therapies targeting the abnormal pH of tumours, alone or in combination with conventional treatments. This concept has been entitled “the buffer therapy” (194). Mathematical models argued that the best buffer to neutralize **pHe** in the **tumour** microenvironment should have a pKa of 7 (208). Even if the pKa of bicarbonate (pKa 6) is not ideal, this is for the moment the best known buffer suitable for systemic administration. The use of bicarbonate gave the first evidence that systemic buffering in mice can reduce **pHe** of tumours (209). Bicarbonate had no effect on primary tumour growth but improved the effect of doxorubicin to reduce tumour volume (209). Furthermore, in a model

of mammary tumour, bicarbonate administration in the drinking water of mice elevated pHe in the tumour and importantly decreased spontaneous metastasis (210). The evaluation of the buffering capacity of food suggests that a new strategy based on a controlled nutritional intake may reduce pHe in the tumour microenvironment and may be effective to improve the efficacy of chemotherapy (211).

In addition, it has been proposed that interfering with pHe and reversing the acidic pH of organelles, using proton pump inhibitors (PPI), would avoid the accumulation of drugs in acidic compartments and would increase their distribution in the cytosol and in the nucleus of cancer cells. Targeting the lysosomal pH using omeprazole, a PPI that is generally used to treat excess stomach acid production and symptoms of gastroesophageal reflux, was demonstrated to improve the cytotoxic effect of doxorubicin, and to decrease tumour volume in a mouse model of osteosarcoma (198). In breast cancer, the other PPI lansoprazole enhanced the therapeutic effect of doxorubicin by both improving its distribution and its cytotoxic activity (212).

#### **2.4. Autophagy and resistance to anticancer treatments**

Autophagy is not specific to tumours, but is definitely an important metabolic pathway that allows cancer cells to degrade their own compartments and components, such as proteins, nucleotides or lipids (in that case called lipophagy), used as energetic substrates to fulfil high anabolic demands required to sustain the enhanced cell proliferation rate and survival under stressful conditions (ischemic episodes, exposure to anticancer treatments) (213) (214-217). Recent studies also suggest that autophagy may be a key inducer of EMT in cancer cells (218,219), further delineating the relationship between metabolism and the acquisition of aggressive parameters, and a potential role in resistance to anticancer treatments. The non-



selective form of autophagy is called macroautophagy (later called autophagy), whereas mitophagy, lipophagy or pexophagy are related to the specific recycling of mitochondria, lipid droplets and peroxisomes, respectively. The chaperone-mediated autophagy is an additional form of autophagy which lacks the formation of an isolation membrane and directly addresses cytosolic proteins containing a consensus pentapeptide for their degradation in lysosomes (220). During the autophagic process, the autophagosome, a double membrane vesicle, is formed and allows for the isolation of non-specific or specific cellular materials to be degraded. In this process, the ATG proteins, encoded by the autophagy-related genes (ATG), are responsible for the conjugation of phosphatidylethanolamine (PE) to LC3 (microtubule-associated protein 1 light chain 3), thus resulting in its incorporation into autophagosome membranes. This is a critical step in autophagosome elongation and maturation, and as such, the presence of LC3-PE, also referred as LC3-II, is often used as a marker of autophagy. The autophagosome then fuses with the lysosomal compartment that provides enzymes. The internal acidification of lysosomes by the V-ATPase is essential for the degradation activity of these proteolytic enzymes. Autophagy can be initiated during nutrients starvation, when the intracellular ATP/ADP ratio becomes low, leading to the activation of the AMPK and the inhibition of the mTOR signalling pathway (221,222), to allow the recycling of amino acids and free fatty acids. This defines the metabolic function of autophagy sustaining cell viability when energetic supplies are reduced, such as in the ischemic regions of tumours. Moreover, autophagy can also assume a protective role against stress conditions, such as **those that generate ROS**. This could be the case under some anticancer therapies, such as radiation therapy or the exposure to chemotherapeutic agents generating oxidative stress, such as anthracyclines (doxorubicin, epirubicin, daunorubicin), alkylating agents, platinum coordination complexes (cisplatin, carboplatin, oxaliplatin), epipodophyllotoxins (etoposide,

teniposide), and the camptothecins (topotecan, irinotecan) (Figure 2). In those cases, autophagy allows for the degradation of dysfunctional organelles and aggregated proteins. Besides these roles of autophagy in response to stressful conditions, the maintenance of a normal autophagic flux is also needed for the physiological function of multiple organs in the whole body, as it is the case in brain, muscle and liver (217,223).

The role of autophagy in tumours is complex and it is now admitted that it could have a dual role in tumour progression (224,225). Studies, in which autophagy genes were knocked-out in mice, evidenced the protective role of autophagy against tumour initiation mainly by inducing oxidative stress (226,227). However, in advanced tumours stages, it has been demonstrated that cancer cells rely on autophagy for their survival, which is favourable for tumour growth and progression (224,228,229). Besides, the stressful conditions of the tumour microenvironment (hypoxia, low nutrients availability, presence of ROS) are known to activate autophagy. In a recent study, we have shown that lactate, which is elevated in tumours because of the elevated glycolytic metabolism, is associated with autophagy (230). In this study, we demonstrate that autophagy is not only activated by nutrient deprivation, but also by lactate. In cancer cells, lactate oxidation by the lactate dehydrogenase B (LDHB) participates to lysosomal acidification to promote autophagy, which is favourable for cancer cell survival and tumour growth. LDHB was found to be in close proximity with the V-ATPase, expressed at the lysosome. It is therefore proposed that the  $H^+$  released by the LDHB, during the conversion of lactate to pyruvate, are transferred to the lysosomal compartment through the activity of the V-ATPase (230).

The ways by which autophagy is regulated by nutrients availability and by the acidic **pHe** in the tumour microenvironment are still poorly understood. Besides its role in lysosomal acidification, the V-ATPase could have an important role in the regulation of autophagy and

subsequent cell growth. Recent evidence shows that **pHi** and lysosomal V-ATPase link glucose metabolism with cell growth. In yeast, the V-ATPase has been considered as being a sensor of the cytosolic pH, in response to glucose availability (231,232). In aerobic conditions, a correlation was found between the concentration of extracellular glucose and a high **pHi**, and this promoted the assembly and the activation of V-ATPase. V-ATPase interacted with the GTPase Arf1 and Gtr1, leading to the activation of TORC1 and Ras to promote cell growth (233). Similarly, the “sensing” of amino acid availability was proposed to be dependent on the V-ATPase and to the Rag GTPase (234,235), but seemed independent on cytosolic pH (233). It has been proposed that this mechanism for **pHi** sensing of glucose metabolism could be conserved in mammals (234) since V-ATPase also interacts with Rag GTPase (mammalian homologue for Gtr1 and Gtr2 in yeast), which promotes mTORC1 activity (235,236). Although the direct involvement of cytosolic pH in the regulation of autophagy is still lacking in mammals, it has been demonstrated that acidic **pHe**, leading to a decrease in **pHi**, inhibits mTORC1, a master negative regulator of autophagy (237). While the mechanistic link is still elusive, one could speculate that the deregulated pH gradient found in cancer cells could regulate cancer cell proliferation through the inhibition of mTORC1 and autophagy.

Autophagy has been described as a process activated during cancer treatment by both radiotherapy and chemotherapy, and was identified as being responsible for tumour resistance (238). The existence of an acidic **pHe** has also been linked with resistance to treatment through the participation of autophagy. In human melanoma and breast cancer cells, both acute and chronic acidosis activate autophagy, probably through PI3K/Akt/mTOR inhibition (239,240). In this context, the activation of autophagy is an adaptative mechanism to acidosis and promotes cancer cell survival. In addition, autophagic markers have been detected in the

outer region of tumours corresponding to hypoxic regions that are probably acidic (240). One contradictory study exists where acidic pH blocks autophagy in non-cancer breast epithelial cells (MCF-10A) and less aggressive breast cancer cells (MCF-7) as compared to MDA-MB-231) (241), suggesting a more complex regulation of autophagy by pHe.

These studies highlighting the influence of the extracellular microenvironment on the regulation of cancer cell survival and autophagy led to the proposition that controlling pHe of tumours might inhibit autophagy and increase anticancer treatment efficacy. In this direction, it has been shown that the use of bicarbonate, as a systemic buffer, decreased the expression of the autophagic marker LC3 in breast tumours (240). Another strategy used to inhibit autophagy through pH modulation was to disrupt lysosomal pH, by repurposing the weak base chloroquine, approved by the Food and Drug Administration (USA) as an antimalarial drug, and its derivatives. In preclinical models, chloroquine effectively reduced autophagy and improved anticancer therapy using alkylating drugs (242). This permitted chloroquine and hydroxychloroquine to be considered for clinical trials for anticancer treatments. The first results of these trials documented safety and pharmacokinetic data of their use, and were very promising (243). However, these weak base compounds present the disadvantage of having a limited diffusion in the acidic extracellular microenvironment of tumours. For this reason, the efficacy of chloroquine to block autophagy was reduced at acidic pH *in vitro* and in the hypoxic region of tumours *in vivo* (244). To counteract these limitations, the autophagy inhibitor salinomycin was proposed to be a possible substitute to chloroquine (245). However, the effects of salinomycin on autophagy seemed to be very complex, and were opposite depending on the dose used (246). Furthermore, these drugs are not specific and act as global pH modulators. As such, the development of specific inhibitors of lysosomal acidification is needed.

In the context of cancer treatment, while the overexpression of autophagy markers in cancer cells and tumours is commonly accepted, the biological consequences of autophagy remain controversial. Several studies have shown that radiation therapy could induce autophagy in cancer cells (247-249), which was supposedly due to a decreased phosphorylation of mTOR (250) and to the involvement of the integrin-associated protein CD47 (251). However, conflicting results were initially obtained, and it is not clear whether autophagy induction in this context is leading to cancer cell death, or their survival. Two different and opposing hypotheses were formulated. The first one was to consider autophagy as a cell death mechanism (“autophagic cell death”) induced by radiations. In this hypothesis, the induction of autophagy would be beneficial to kill cancer cells, and it should be enhanced. However, the term “autophagic cell death” has been considered as being a misnomer, and to be in fact cell death associated with markers of autophagy, rather than being a specific type of cell death (252,253). The second hypothesis, which recently gained more insights, is to consider autophagy as a survival mechanism involved in cancer cell resistance to radiotherapy, and in that case, its inhibition would be beneficial to cancer treatment. This hypothesis is supported by the demonstration that, in cells deficient for autophagy, radiations induced the accumulation of p62, which inhibited the recruitment of DNA-repairing factors such as UIMC1/RAP80, BRCA1 and RAD51 to double strand break sites, leading to impaired DSB repair and decreased cell survival (254). Clinical trials with hydroxychloroquine and radiation therapy gave promising results (255). Few studies investigate the role of acidic **pHe** involvement for radiation therapy but it has been evidenced that at acidic pH, radiations induced less apoptosis (256). It has also been proposed to use PPI to overcome the autophagy induced by chemotherapies. This idea has brought some hopeful results with omeprazole, which was effective in re-establishing chemosensitivity of resistant melanoma cells to

cisplatin (257), and with pantoprazole, also enhancing the efficacy of docetaxel on the growth of human tumour xenografts by inhibiting autophagy (258). At this point, it is probably worth mentioning that the apparent contradictions on the biological significance of autophagy induction during anticancer treatment might also differ as a function of the level of induction and its persistence in time. Furthermore, autophagy is also important for anticancer or permissive immune response. It has been proposed that activating autophagy could improve an anticancer immune response and radiation therapy (259).

### **3. The perspectives of using dietary lipids for an integrated strategy in the treatment of cancers**

The molecular mechanisms of the cancer hallmarks mentioned above are/can be targeted by specific drugs interfering with deregulated pH in cancer cells, such as the use of pH buffers (210), or drugs inhibiting H<sup>+</sup> transporters (260-262) or their key regulators (174), alone or in combination with conventional chemotherapeutics. This strategy seems to be very promising, at least at the basic research level and in pre-clinical models, but needs to be further studied in clinical trials. Another tempting strategy would be to identify molecules that have the capacity to target more than one of these mechanisms without displaying adverse side effect. Dietary lipids might be of interest to do so. Indeed, cancers are diseases for which the development and progression are also under the dependence of environmental factors that present the benefit of being modifiable. This is the case of nutritional factors. Some dietary compounds have been recognized to influence both the apparition and the survival to different carcinoma.

The adipose tissue plays an essential function in the storage of lipids, such as fatty acids and sterols, and it is a qualitative biomarker of past dietary fatty acids intake. Being in close

proximity to multiple epithelial tissues, such as the adipose tissue in the mammary gland, the periprostatic adipose tissue, or the mesenteric adipose tissue close to the colorectal tracts, the adipose tissue has been shown to importantly control primary tumour progression and may influence clinical markers of tumour aggressiveness (Figure 3).

Lipids, such as polyunsaturated fatty acids (PUFA, such as n-6 or n-3 PUFA) and sterols have been proposed to regulate, either positively or negatively, tumour development and disease progression by modulating cellular properties in both cancer and non-cancer cells of the tumour microenvironment. Studies performed on breast cancer have already demonstrated the importance of adipose tissue and epithelial tissue fatty acid composition, from triacylglycerids and phospholipids, respectively, on breast tumour development. Among dietary lipids, long chain n-3 PUFA, from marine fatty fishes, have been identified from epidemiological studies for their potential to prevent the appearance of breast cancer (263,264). From *in vivo* and *in vitro* studies, n-3 PUFA have been reported to have multiple anti-tumour effects and their dietary consumption was associated with a lower risk of cancers, such as breast or colorectal cancers (264-266). Also, they have been shown to reduce chronic inflammation associated with these cancer types (263,264,267). Even though n-3 PUFA were suggested to be prostate cancer suppressor (268), their beneficial effect is not that clear and more intervention trials or observational studies are still required (269).

#### *-Primary tumour growth and resistance to treatment-*

Following up on previous work on the lipidome, that associated the risk of breast cancer to the lipid composition (270,271), a recent pilot study showed that fatty acid composition of breast adipose tissue differed according to breast cancer focality. Low levels of DHA and EPA in breast adipose tissue were associated with tumour multifocality, a marker

of cancer aggressiveness (272). These results could indicate that differences in lipid content may contribute to mechanisms through which peritumoral adipose tissue drives breast cancer aggressiveness.

Developing approaches that can improve the selectivity and efficacy of anticancer drugs, while limiting their side effects, remains a challenge. Long-chain n-3 PUFA have been attributed the potential to increase tumour sensitivity to chemotherapy with no sensitization of normal tissues (264). DHA and EPA have generated intense interest due to their ability to reduce resistance to anthracyclines, taxanes or radiotherapy, without additional side effects, in mammary tumour models. The efficacy of numerous anticancer drugs on breast cancer cell lines and rodent mammary tumours may be enhanced by treatment with DHA.

In the case of breast cancer, n-3 PUFAs supplementations were proposed to have beneficial effects in reducing primary tumour growth (Figure 3). This was attributed to their potency to inhibit cancer cell proliferation (273). Docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) decreased the proliferation of human MDA-MB-231 breast cancer cells through the regulation of the cell cycle. Both DHA and EPA increased the duration of the G2/M phase, while there was no alteration of G1 or S phases. These two fatty acids decreased the expression of cyclin A, cyclin B1 and cyclin-dependent kinase 1. Upon n-3 PUFA treatment, cyclin B1 phosphorylation was inhibited and the expression of the cell division cycle 25C phosphatase, which dephosphorylates cyclin-dependent kinase 1, was decreased (273).

Different molecular mechanisms such as the amplification of oxidative stress generated by anthracyclines or radiotherapy and increased accumulation of anticancer agents have been proposed to account for the effects of these highly peroxidable fatty acids. In a phase II clinical trial performed with breast cancer patients with severe metastatic disease, a diet



enriched with DHA (1.8 g daily) increased time to progression from 3.5 months for patients not incorporating DHA, to 8.7 months for patients incorporating DHA (Bougnoux et al, 2009). In parallel to this type of nutritional intervention in breast cancer patients under chemotherapy, original modes of action by which DHA can sensitize mammary tumours to anticancer agents have been uncovered in a rat model of N-nitroso-N-methylurea (NMU)-induced mammary tumours. In this breast cancer model, DHA supplementation enhanced DHA tumour content in a time- and dose-dependent manner (274-276). DHA is a natural ligand for the nuclear peroxisome proliferator-activated receptors (PPAR), and in the (NMU)-induced mammary tumour model, a reduced expression level of PPAR $\beta$  mRNA correlated with regression of mammary tumours. Tumours that most regressed displayed the most reduced PPAR $\beta$  mRNA expression. In addition, PPAR $\beta$  regulated DHA-induced growth inhibition of MDA-MB-231 and MCF-7 cells, identifying PPAR $\beta$  as an important player for the inhibition of breast cancer cell growth and mammary tumour growth with a DHA diet (277).

As already mentioned, an important limitation of cancer treatment is the acquisition by the tumour of a resistance to chemotherapeutic agents. Resistance to taxanes can occur by the induction of signalling pathways such as PI3K/Akt and ERK1/2, which promote survival and cell growth in human cancer cells. In docetaxel-treated MDA-MB-231 cells, phosphorylated-ERK1/2 levels were increased by 60% in both membrane and nuclear compartments, compared to untreated cells and ERK1/2 activation depended on PKC $\epsilon$  and PKC $\delta$  activation. In DHA-supplemented cells, docetaxel was unable to increase PKC $\epsilon$  and PKC $\delta$  levels in membrane and nuclear fractions, resulting in both diminished ERK1/2 phosphorylation and increased docetaxel efficacy. Reduced membrane levels of PKC $\epsilon$  and PKC $\delta$  were associated with significant incorporation of DHA in all phospholipid classes, including in

phosphatidylcholine, which is a major source of phosphatidic acid. Additionally, study of the Akt pathway showed that DHA could repress docetaxel-induced Ser473Akt phosphorylation. In rat NMU-induced mammary tumours, dietary DHA supplementation during docetaxel chemotherapy repressed ERK and Akt survival pathways and, in turn, strongly improved taxane efficacy. P-ERK1/2 levels were negatively correlated with tumour regression. These findings could be of potential clinical importance for the treatment of chemotherapy-resistant cancer (278).

In addition to their antitumour activities reported in epithelial cancer cells, it was demonstrated that n-3 PUFA could increase the efficacy of the chemotherapeutic treatment by remodelling the vascular network in mammary tumours, thereby contributing to more efficient drug delivery (279). Functional vascular parameters (vascularization measured by ultrasounds, interstitial fluid pressure IFP) were determined for two nutritional groups, control and n-3 UFA-enriched diet, of female rats bearing NMU-induced mammary tumours. Whereas docetaxel stabilized tumour growth in the control group, it induced a 50% tumour regression in the n-3 PUFA group. Before the first treatment with docetaxel, there was an apparent remodelling of the tumour vasculature with smaller vessels in the n-3 PUFA group. Ultrasounds parameters were consistently lower in the n-3 PUFA group at all time-points measured, down to 50% at the end of the docetaxel treatment. A single dose of docetaxel in the n-3 PUFA group markedly reduced IFP as early as 2 hours after the first injection of docetaxel and this reduction was maintained for one week, at a time when Evans blue extravasation was increased by 3-fold. A decreased activation of endothelial nitric oxide synthase in tumours of the n-3 PUFA group, and *in vitro*, in human endothelial cells cultured with n-3 PUFA, points toward a PUFA-induced disruption of nitric oxide (NO) signalling pathway (279). Using an original contrast-enhanced ultrasound method (280), the vascular

architecture was analysed during docetaxel treatment of mammary tumours in rats fed with control or n-3 PUFA diets. The vascular network was remodelled in favour of smaller vessels (microvascularization) in the n-3 PUFA tumours, and this correlated with an improved response to docetaxel chemotherapy. Analysis of angiogenesis-related gene expression using PCR arrays showed that the expression of epiregulin and amphiregulin were reduced in tumours of the n-3 PUFA group. This was correlated with tumour regression after chemotherapy. *In vitro* studies showed that epiregulin and amphiregulin expression were strongly induced by VEGF in primary endothelial cells. DHA supplementation repressed only epiregulin gene expression and counteracted VEGF activities on proliferation and pseudo-capillaries formation. The normalization of tumour vasculature under n-3 PUFA diet indicated that such a supplementation, by improving drug delivery in mammary tumours, could be a complementary clinical strategy to decrease anticancer drug resistance (281) (Figure 3).

*- Cancer cell metabolism and autophagy-*

While there are several reports that n-3 PUFA could induce apoptosis in cancer cells, mainly through the formation of ROS,  $Ca^{2+}$  accumulation and opening of the mitochondrial permeability transition pore (MPTP) (282) or caspase activation (283,284), there are relatively few data concerning the potential regulation of cancer cell metabolism. It is however tempting to speculate that these long chain n-3 PUFA could also modulate or normalize cancer cell bioenergetics, acting through a modulation of the aerobic glycolysis as well as on the mitochondrial activity.

In a recent study focusing on colorectal carcinogenesis, male Wistar rats received a weekly intraperitoneal injections of ethylenediamine tetra-acetic acid (EDTA) or N,N-dimethylhydrazine dihydrochloride (DMH) for a period of 4 weeks, responsible for the

initiation and post-initiation phase, respectively (285). These groups were subdivided into dietary groups, a control group, a group receiving fish oil and corn oil in similar proportions (1:1) and an n-3 PUFA-enriched group receiving fish oil and corn oil in 2.5:1 proportions. DMH treatment induced a mitochondrial degeneration, disrupted cristae and a significant decrease in electron transport chain complexes activity, reflecting carcinogenic-associated metabolic reprogramming. This was associated with an increase in cholesterol and cardiolipin levels in post-initiation phase, suggested to provoke a loss of apoptotic activity. Interestingly, fish oil diet in both the ratios stabilized or increased the number of mitochondria. The diet the more enriched in fish oil induced mitophagy, along with modulation of the electron transport chain complexes activity, decreased cholesterol and cardiolipin (a specific phospholipid of mitochondrial membranes containing four acyl chains) levels, thus facilitating apoptosis and attenuating carcinogenesis (285).

In PC3 prostate cancer cells, treating the cells with fish oil, containing 90% ethyl ester n-3 fatty acid among which 40% DHA, 40% EPA, and 10% other n-3 PUFA, induced important phosphoproteomic changes as compared to a control group treated with oleic acid. Particularly relevant are the phosphorylation levels of the two regulatory serine residues in pyruvate dehydrogenase alpha 1 (PDHA1), serine-232 and serine-300, which were significantly decreased upon fish oil treatment, resulting in the increase of pyruvate dehydrogenase (PDH) activity. Results brought by this study supported the protective role of n-3 PUFA in prostate cancer through the suppression of aerobic glycolysis by restoring PDH activity, and in controlling the balance between lipid and glucose oxidation (286).

Metabolic investigation were also performed in breast cancer cells showing respiratory (BT-474 cell line) or glycolytic (MDA-MB-231 cell line) phenotypes, compared to non-cancer MCF-10 mammary cells, and revealed that DHA supplementation significantly

diminished the cancer cell metabolism and glycolytic profile of malignant cell lines in a dose-dependent manner (287). DHA enrichment decreased HIF-1 $\alpha$  levels and transcriptional activity in the malignant cell lines but not in the non-transformed cell line. Consequently, downstream targets of HIF-1 $\alpha$ , such as GLUT-1 and LDH, were decreased by DHA treatment in the BT-474 cell line, as well as in the MDA-MB-231 cell line. Correlatively, DHA supplementation decreased glucose uptake and oxidation, glycolytic metabolism, and lactate production. DHA induced a decrease of intracellular ATP in both cancer cell lines. This resulted in the phosphorylation of AMP-activated protein kinase (AMPK, at Thr172) as a metabolic stress marker. These important results indicated that DHA could alter cancer cell growth and survival by modulating cancer cell metabolism, while not affecting the one of non-cancer cells (287). By specifically interfering with cancer cell metabolism, the supplementation with n-3 PUFA (such as DHA) could be considered as an opportunity to inhibit cancer cell survival and tumour progression (288).

Recent data have shown that n-3 PUFA could regulate autophagy, which could be involved in both survival and apoptosis of cancer cells, depending on the carcinogenetic phase and on the treatment context. In a study conducted in cervical, breast and lung cancer cells, DHA was found to induce apoptosis and to increase the number of autophagic vacuoles without impairing autophagic vesicle turnover. The induction of autophagy was mediated by p53. DHA-induced autophagy was associated with p53 loss, and to the activation of AMPK and the decrease in the activity of mTOR. Autophagy inhibition suppressed apoptosis, and further autophagy induction enhanced apoptosis in response to DHA treatment (289).

Another study performed in the context of colon carcinogenesis studied the effects of DHA on cancer cell differentiation or programmed cell death involving mitochondrial pathway

induced by sodium butyrate. Sodium butyrate induced autophagy both in HT-29 and HCT-116 cells, which are sensitive and insensitive to the induction of differentiation, respectively. However, autophagy supported cell survival only in HT-29 cells. DHA promoted cell death and activated PPAR $\gamma$  in both cell types. The inhibition of autophagy both attenuated differentiation and enhanced apoptosis in HT-29 cells treated with sodium butyrate and DHA, but was ineffective in HCT-116 cells. PPAR $\gamma$  silencing decreased differentiation and increased apoptosis only in HT-29 cells. Thus, authors suggested that diverse responses of colon cancer cells to fatty acids might rely on their level of differentiation, which may in turn depend on distinct engagement of autophagy (290).

DHA treatment induced oxidative stress in SW620 and Caco-2 colon cancer cells. DHA inhibited the growth of SW620 cells and induced transcriptional regulation of genes involved in oxidative stress response and autophagy. However, the oxidative stress response was not the cause of DHA-induced cytotoxicity in SW620 cells. Inhibition of autophagy sensitized both SW620 and Caco-2 cells to DHA. Autophagy stimulation resulted in decreased DHA-sensitivity of SW620 cells that have a low basal level of autophagy, while inhibition of autophagy in Caco-2 cells, displaying a higher level of basal autophagy, resulted in increased DHA-sensitivity. Taken together, these results indicated that autophagy was important for the DHA sensitivity of colon cancer cells (291).

#### *-EMT and Invasive properties –*

As already mentioned, EMT is a key step in the acquisition of aggressiveness in cancer cells, through increased invasive properties and resistance to treatments. To date, there is no potent pharmacological strategy to prevent EMT. Again, there is evidence that n-3 PUFA may

inhibit the expression of EMT markers and reduce associated invasive properties in cancer cells (Figure 3).

A recent study indicated that the supplementation of colorectal cancer cells with DHA, inhibited the expression of the serine protease Granzyme B, characterized as being an EMT inducer, and therefore inhibited the expression of Snail1 and N-cadherin while overexpressing E-cadherin. DHA treatment also resulted in a reduction of colorectal cancer cell invasiveness (292). These results supported the use of DHA, a dietary compound without toxic effects, as an adjuvant in colorectal cancer therapy.

Similarly, it was found that increasing the endogenous levels of n-3 PUFA, using n-3 fatty acid desaturase (fat-1) transgenic mice, was associated with a reduction in the growth rate of melanoma xenografts. This reduction in melanoma growth in fat-1 mice, compared with wild-type mice, was associated with an increased expression of E-cadherin and the reduced expression of its transcriptional repressors, Zeb-1 and Snail-1 (293). It also significantly repressed the EGFR/Akt/ $\beta$ -catenin signalling pathway and induced the formation of significant levels of anti-inflammatory n-3 PUFA-derived lipid mediators, such as resolvins D2 and E1, maresin 1 and 15-hydroxyeicosapentaenoic acid (293).

While it is commonly accepted, since a long time now, that n-3 PUFA have anti-invasive and anti-metastatic properties (264,294-297), molecular details for these effects are not fully described. One possible explanation is the repression of EMT, but again, the clear mechanism for this remains to be elucidated. **Importantly, n-3 PUFA, through the activation of PPAR $\gamma$ , have been shown to down-regulate the expression of NHE1 and to reduce cancer colony growth (298). This inhibition of NHE1 expression could also be responsible for the anti-invasive activity of these fatty acids.** What is known is that these fatty acids can, in their

native non-peroxidated or peroxidated forms, modulate the activity of NHE exchangers (299,300), and of ion channels (301,302) that have been demonstrated to be key regulators of cancer cell invasiveness (295). **An important mode of regulation by n-3 PUFA is the change of physico-chemical properties of cell membranes after their incorporation into phospholipids, notably in lipid raft domains (303). Indeed, DHA and EPA have been shown to have protective effects by affecting NHE1 activity through a non-genotoxic pathway associated with plasma membrane remodelling (304).**

This is the case for the  $\text{Na}_v1.5$  channel, importantly regulating the invasive properties of breast and colorectal cancer cells (170,305,306), which activity was initially found to be inhibited in expression systems or in native rat cardiomyocytes (307,308). As such, n-3 PUFAs have been proposed to exert their beneficial effect on cancers through a reduction of the activity of  $\text{Na}_v1.5$ , such as it would have beneficial cardiac anti-arrhythmic effects (295,309). In initial studies performed in Alexander Leaf's group, n-3 PUFA were found to directly bind to the channel and to inhibit its activity (310,311). However, contrasting results were obtained in human breast cancer cells in which  $\text{Na}_v1.5$  channel, which is expressed under the form of a neonatal splice variant (167), was not inhibited by acute application of n-3 PUFA, even at high concentrations (30-50  $\mu\text{M}$ ) (312). In fact, growing breast cancer cells in the presence of low doses of DHA (0.5 to 10  $\mu\text{M}$ ) reduced *SCN5A* gene expression and levels of  $\text{Na}_v1.5$  proteins and related sodium current (312,313). The inhibition of *SCN5A* expression was mediated by the lipid-sensitive nuclear receptor  $\text{PPAR}\beta$ . This inhibition of  $\text{Na}_v1.5$  activity was responsible for a reduced activity of NHE1, decreasing  $\text{H}^+$  efflux, resulting in a limited extracellular acidification, a reduced proteolytic activity and the inhibition of breast cancer cell mesenchymal invasion (312). In this context, one could postulate that DHA would also limit cell migration and resistance to treatment that are



properties related to pH regulation, in all cancer cells showing functional  $\text{Na}_v1.5\text{-NHE1}$  complexes.

Altogether, these studies provide mechanistic, pre-clinical and clinical information that dietary supplementations of n-3 PUFA might represent new powerful opportunities to normalise cancer cell metabolism, limit the aggressive progression of some cancer types and prevent the resistance to anticancer treatments (Figure 3).

#### **4. Conclusions**

## **Conflict of interests**

Authors declare no conflict of interest.

## **Acknowledgements**

We thank all our colleagues from the Inserm UMR1069 for all constructive discussion and Mrs Catherine Le Roy for secretary and administrative assistance. The work performed at the Inserm UMR1069 was supported by the "Ministère de la Recherche et des Technologies", the Inserm, the "Ligue Nationale Contre le Cancer – Interrégion Grand-Ouest", the Région Centre-Val de Loire (grant "NavMetarget", project "ARD2020 Biomédicaments"), the CHU of Tours, the "Association CANCEN", the "Studium" and the "Cancéropole Grand-Ouest". SR is supported by the Institut Universitaire de France (IUF).

## 5. References

1. Torre, L. A., Siegel, R. L., Ward, E. M., and Jemal, A. (2016) Global Cancer Incidence and Mortality Rates and Trends--An Update. *Cancer Epidemiol Biomarkers Prev* **25**, 16-27
2. McCubrey, J. A., Rakus, D., Gizak, A., Steelman, L. S., Abrams, S. L., Lertpiriyapong, K., Fitzgerald, T. L., Yang, L. V., Montalto, G., Cervello, M., Libra, M., Nicoletti, F., Scalisi, A., Torino, F., Fenga, C., Neri, L. M., Marmiroli, S., Cocco, L., and Martelli, A. M. (2016) Effects of mutations in Wnt/beta-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. *Biochim Biophys Acta* **1863**, 2942-2976
3. Patel, A., Sabbineni, H., Clarke, A., and Somanath, P. R. (2016) Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. *Life Sci* **157**, 52-61
4. Zhan, T., Rindtorff, N., and Boutros, M. (2016) Wnt signaling in cancer. *Oncogene*
5. Hobbs, G. A., Der, C. J., and Rossman, K. L. (2016) RAS isoforms and mutations in cancer at a glance. *J Cell Sci* **129**, 1287-1292
6. Land, H., Parada, L. F., and Weinberg, R. A. (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature* **304**, 596-602
7. Knudson, A. G., Jr. (1971) Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* **68**, 820-823
8. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. *Science* **249**, 912-915
9. Dyson, N. J. (2016) RB1: a prototype tumor suppressor and an enigma. *Genes & development* **30**, 1492-1502
10. Kleibl, Z., and Kristensen, V. N. (2016) Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. *Breast* **28**, 136-144
11. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. *Cell* **100**, 57-70
12. Fidler, I. J. (2003) Understanding bone metastases: the key to the effective treatment of prostate cancer. *Clinical advances in hematology & oncology : H&O* **1**, 278-279
13. Gupta, G. P., and Massague, J. (2006) Cancer metastasis: building a framework. *Cell* **127**, 679-695
14. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005) Global cancer statistics, 2002. *CA Cancer J Clin* **55**, 74-108
15. Friedl, P., and Alexander, S. (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. *Cell* **147**, 992-1009
16. Friedl, P., Locker, J., Sahai, E., and Segall, J. E. (2012) Classifying collective cancer cell invasion. *Nat Cell Biol* **14**, 777-783
17. Yang, J., and Weinberg, R. A. (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Dev Cell* **14**, 818-829

18. Gonzalez, D. M., and Medici, D. (2014) Signaling mechanisms of the epithelial-mesenchymal transition. *Sci Signal* **7**, re8
19. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J., and Weinberg, R. A. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704-715
20. Scheel, C., and Weinberg, R. A. (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. *Semin Cancer Biol* **22**, 396-403
21. Tam, W. L., and Weinberg, R. A. (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. *Nat Med* **19**, 1438-1449
22. Labelle, M., Begum, S., and Hynes, R. O. (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell* **20**, 576-590
23. Heldin, C. H., Vanlandewijck, M., and Moustakas, A. (2012) Regulation of EMT by TGFbeta in cancer. *FEBS Lett* **586**, 1959-1970
24. McCormack, N., and O'Dea, S. (2013) Regulation of epithelial to mesenchymal transition by bone morphogenetic proteins. *Cell Signal* **25**, 2856-2862
25. Yilmaz, M., and Christofori, G. (2009) EMT, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev* **28**, 15-33
26. Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., and Weinberg, R. A. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Res* **68**, 3645-3654
27. Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R. A. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* **117**, 927-939
28. Batlle, E., Sancho, E., Franci, C., Dominguez, D., Monfar, M., Baulida, J., and Garcia De Herreros, A. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat Cell Biol* **2**, 84-89
29. Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., and Nieto, M. A. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol* **2**, 76-83
30. Mimeault, M., and Batra, S. K. (2013) Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. *J Cell Mol Med* **17**, 30-54
31. Linder, S., Wiesner, C., and Himmel, M. (2011) Degrading devices: invadosomes in proteolytic cell invasion. *Annu Rev Cell Dev Biol* **27**, 185-211
32. Brisson, L., Reshkin, S. J., Gore, J., and Roger, S. (2012) pH regulators in invadosomal functioning: Proton delivery for matrix tasting. *Eur J Cell Biol* **91**, 847-860
33. Busco, G., Cardone, R. A., Greco, M. R., Bellizzi, A., Colella, M., Antelmi, E., Mancini, M. T., Dell'Aquila, M. E., Casavola, V., Paradiso, A., and Reshkin, S. J. (2010) NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. *Faseb J* **24**, 3903-3915

34. Glunde, K., Guggino, S. E., Solaiyappan, M., Pathak, A. P., Ichikawa, Y., and Bhujwalla, Z. M. (2003) Extracellular acidification alters lysosomal trafficking in human breast cancer cells. *Neoplasia* **5**, 533-545
35. Wolf, K., and Friedl, P. (2011) Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. *Trends Cell Biol* **21**, 736-744
36. Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., Sahai, E., and Marshall, C. J. (2008) Rac activation and inactivation control plasticity of tumor cell movement. *Cell* **135**, 510-523
37. Sahai, E., and Marshall, C. J. (2003) Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. *Nat Cell Biol* **5**, 711-719
38. Wyckoff, J. B., Pinner, S. E., Gschmeissner, S., Condeelis, J. S., and Sahai, E. (2006) ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. *Curr Biol* **16**, 1515-1523
39. Friedl, P., and Wolf, K. (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. *Nat Rev Cancer* **3**, 362-374
40. Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Bocker, E. B., and Friedl, P. (2003) Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. *J Cell Biol* **160**, 267-277
41. Lah, T. T., Duran Alonso, M. B., and Van Noorden, C. J. (2006) Antiprotease therapy in cancer: hot or not? *Expert opinion on biological therapy* **6**, 257-279
42. Bergert, M., Chandradoss, S. D., Desai, R. A., and Paluch, E. (2012) Cell mechanics control rapid transitions between blebs and lamellipodia during migration. *Proc Natl Acad Sci U S A* **109**, 14434-14439
43. Bon, E., Driffort, V., Gradek, F., Martinez-Caceres, C., Anchelin, M., Pelegrin, P., Cayuela, M. L., Marionneau-Lambot, S., Oullier, T., Guibon, R., Fromont, G., Gutierrez-Pajares, J. L., Domingo, I., Piver, E., Moreau, A., Burlaud-Gaillard, J., Frank, P. G., Chevalier, S., Besson, P., and Roger, S. (2016) SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer. *Nature communications* **7**, 13648
44. Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C. C., LeBleu, V. S., and Kalluri, R. (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature* **527**, 525-530
45. Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T., Choi, H., El Rayes, T., Ryu, S., Troeger, J., Schwabe, R. F., Vahdat, L. T., Altorki, N. K., Mittal, V., and Gao, D. (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. *Nature* **527**, 472-476
46. Penkert, J., Ripperger, T., Schieck, M., Schlegelberger, B., Steinemann, D., and Illig, T. (2016) On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. *Oncotarget*
47. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. *Cell* **144**, 646-674
48. Webb, B. A., Chimenti, M., Jacobson, M. P., and Barber, D. L. (2011) Dysregulated pH: a perfect storm for cancer progression. *Nat Rev Cancer* **11**, 671-677

49. Strickaert, A., Saiselet, M., Dom, G., De Deken, X., Dumont, J. E., Feron, O., Sonveaux, P., and Maenhaut, C. (2016) Cancer heterogeneity is not compatible with one unique cancer cell metabolic map. *Oncogene*
50. Payen, V. L., Porporato, P. E., Baselet, B., and Sonveaux, P. (2016) Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. *Cell Mol Life Sci* **73**, 1333-1348
51. Porporato, P. E., Payen, V. L., Baselet, B., and Sonveaux, P. (2016) Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. *Cell Mol Life Sci* **73**, 1349-1363
52. Fearon, K. C., Glass, D. J., and Guttridge, D. C. (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell metabolism* **16**, 153-166
53. Dumas, J. F., Goupille, C., Julienne, C. M., Pinault, M., Chevalier, S., Bougnoux, P., Servais, S., and Couet, C. (2011) Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis. *Journal of hepatology* **54**, 320-327
54. Julienne, C. M., Dumas, J. F., Goupille, C., Pinault, M., Berri, C., Collin, A., Tesseraud, S., Couet, C., and Servais, S. (2012) Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. *Journal of cachexia, sarcopenia and muscle* **3**, 265-275
55. Petruzzelli, M., and Wagner, E. F. (2016) Mechanisms of metabolic dysfunction in cancer-associated cachexia. *Genes & development* **30**, 489-501
56. Porporato, P. E. (2016) Understanding cachexia as a cancer metabolism syndrome. *Oncogenesis* **5**, e200
57. Gillies, R. J., Raghunand, N., Karczmar, G. S., and Bhujwala, Z. M. (2002) MRI of the tumor microenvironment. *J Magn Reson Imaging* **16**, 430-450
58. Gilkes, D. M., Semenza, G. L., and Wirtz, D. (2014) Hypoxia and the extracellular matrix: drivers of tumour metastasis. *Nat Rev Cancer* **14**, 430-439
59. Wenger, R. H. (2002) Cellular adaptation to hypoxia: O<sub>2</sub>-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O<sub>2</sub>-regulated gene expression. *FASEB J* **16**, 1151-1162
60. Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., and Semenza, G. L. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. *Cancer Cell* **11**, 407-420
61. Dang, C. V., Kim, J. W., Gao, P., and Yustein, J. (2008) The interplay between MYC and HIF in cancer. *Nat Rev Cancer* **8**, 51-56
62. Semenza, G. L., Roth, P. H., Fang, H. M., and Wang, G. L. (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. *J Biol Chem* **269**, 23757-23763
63. Kim, J. W., Gao, P., Liu, Y. C., Semenza, G. L., and Dang, C. V. (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. *Mol Cell Biol* **27**, 7381-7393
64. Semenza, G. L. (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. *Sci STKE* **2007**, cm8
65. Warburg, O., Wind, F., and Negelein, E. (1927) The Metabolism of Tumors in the Body. *J Gen Physiol* **8**, 519-530

66. Warburg, O. (1956) On the origin of cancer cells. *Science* **123**, 309-314
67. Gatenby, R. A., and Gillies, R. J. (2004) Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* **4**, 891-899
68. Shaw, R. J. (2006) Glucose metabolism and cancer. *Curr Opin Cell Biol* **18**, 598-608
69. Gambhir, S. S. (2002) Molecular imaging of cancer with positron emission tomography. *Nat Rev Cancer* **2**, 683-693
70. Warburg, O. (1956) On respiratory impairment in cancer cells. *Science* **124**, 269-270
71. Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., Pestell, R. G., Martinez-Outschoorn, U. E., Sotgia, F., and Lisanti, M. P. (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle* **8**, 3984-4001
72. Sotgia, F., Martinez-Outschoorn, U. E., and Lisanti, M. P. (2014) The reverse Warburg effect in osteosarcoma. *Oncotarget* **5**, 7982-7983
73. Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., Yamada, S. D., Peter, M. E., Gwin, K., and Lengyel, E. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med* **17**, 1498-1503
74. Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O., and Dewhirst, M. W. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. *J Clin Invest* **118**, 3930-3942
75. Guillaumond, F., Leca, J., Olivares, O., Lavaut, M. N., Vidal, N., Berthezene, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., Iovanna, J. L., Tomasini, R., and Vasseur, S. (2013) Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. *Proc Natl Acad Sci U S A* **110**, 3919-3924
76. Tan, A. S., Baty, J. W., Dong, L. F., Bezawork-Geleta, A., Endaya, B., Goodwin, J., Bajzikova, M., Kovarova, J., Peterka, M., Yan, B., Pesdar, E. A., Sobol, M., Filimonenko, A., Stuart, S., Vondrusova, M., Kluckova, K., Sachaphibulkij, K., Rohlena, J., Hozak, P., Truksa, J., Eccles, D., Haupt, L. M., Griffiths, L. R., Neuzil, J., and Berridge, M. V. (2015) Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. *Cell metabolism* **21**, 81-94
77. LeBleu, V. S., O'Connell, J. T., Gonzalez Herrera, K. N., Wikman, H., Pantel, K., Haigis, M. C., de Carvalho, F. M., Damascena, A., Domingos Chinen, L. T., Rocha, R. M., Asara, J. M., and Kalluri, R. (2014) PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nat Cell Biol* **16**, 992-1003, 1001-1015
78. Chen, E. I., Hewel, J., Krueger, J. S., Tiraby, C., Weber, M. R., Kralli, A., Becker, K., Yates, J. R., 3rd, and Felding-Habermann, B. (2007) Adaptation of energy metabolism in breast cancer brain metastases. *Cancer Res* **67**, 1472-1486
79. Santidrian, A. F., Matsuno-Yagi, A., Ritland, M., Seo, B. B., LeBoeuf, S. E., Gay, L. J., Yagi, T., and Felding-Habermann, B. (2013) Mitochondrial complex I activity and NAD<sup>+</sup>/NADH balance regulate breast cancer progression. *J Clin Invest* **123**, 1068-1081

80. Han, X. J., Yang, Z. J., Jiang, L. P., Wei, Y. F., Liao, M. F., Qian, Y., Li, Y., Huang, X., Wang, J. B., Xin, H. B., and Wan, Y. Y. (2015) Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells. *Int J Oncol* **46**, 691-700
81. Che, T. F., Lin, C. W., Wu, Y. Y., Chen, Y. J., Han, C. L., Chang, Y. L., Wu, C. T., Hsiao, T. H., Hong, T. M., and Yang, P. C. (2015) Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. *Oncotarget* **6**, 37349-37366
82. Han, D., Williams, E., and Cadenas, E. (2001) Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. *Biochem J* **353**, 411-416
83. Cadenas, E., and Davies, K. J. (2000) Mitochondrial free radical generation, oxidative stress, and aging. *Free Radic Biol Med* **29**, 222-230
84. Hung, W. Y., Huang, K. H., Wu, C. W., Chi, C. W., Kao, H. L., Li, A. F., Yin, P. H., and Lee, H. C. (2012) Mitochondrial dysfunction promotes cell migration via reactive oxygen species-enhanced beta5-integrin expression in human gastric cancer SC-M1 cells. *Biochim Biophys Acta* **1820**, 1102-1110
85. Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., and Hayashi, J. (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. *Science* **320**, 661-664
86. Goh, J., Enns, L., Fatemie, S., Hopkins, H., Morton, J., Pettan-Brewer, C., and Ladiges, W. (2011) Mitochondrial targeted catalase suppresses invasive breast cancer in mice. *BMC Cancer* **11**, 191
87. Porporato, P. E., Payen, V. L., Perez-Escuredo, J., De Saedeleer, C. J., Danhier, P., Copetti, T., Dhup, S., Tardy, M., Vazeille, T., Bouzin, C., Feron, O., Michiels, C., Gallez, B., and Sonveaux, P. (2014) A mitochondrial switch promotes tumor metastasis. *Cell reports* **8**, 754-766
88. Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R. G., Chiavarina, B., Frank, P. G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U. E., Sotgia, F., and Lisanti, M. P. (2010) Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle* **9**, 3506-3514
89. Pavlides, S., Vera, I., Gandara, R., Sneddon, S., Pestell, R. G., Mercier, I., Martinez-Outschoorn, U. E., Whitaker-Menezes, D., Howell, A., Sotgia, F., and Lisanti, M. P. (2012) Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. *Antioxidants & redox signaling* **16**, 1264-1284
90. Sotgia, F., Whitaker-Menezes, D., Martinez-Outschoorn, U. E., Flomenberg, N., Birbe, R. C., Witkiewicz, A. K., Howell, A., Philp, N. J., Pestell, R. G., and Lisanti, M. P. (2012) Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. *Cell Cycle* **11**, 1445-1454
91. Alvero, A. B., Montagna, M. K., Holmberg, J. C., Craveiro, V., Brown, D., and Mor, G. (2011) Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. *Mol Cancer Ther* **10**, 1385-1393
92. Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., Widger, W., Ellis, L. M., and Weihua, Z. (2012) Intracellular ATP levels



- are a pivotal determinant of chemoresistance in colon cancer cells. *Cancer Res* **72**, 304-314
93. Shin, Y. K., Yoo, B. C., Chang, H. J., Jeon, E., Hong, S. H., Jung, M. S., Lim, S. J., and Park, J. G. (2005) Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. *Cancer Res* **65**, 3162-3170
  94. Li, Y. C., Fung, K. P., Kwok, T. T., Lee, C. Y., Suen, Y. K., and Kong, S. K. (2004) Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. *Chemotherapy* **50**, 55-62
  95. Munteanu, E., Verdier, M., Grandjean-Forestier, F., Stenger, C., Jayat-Vignoles, C., Huet, S., Robert, J., and Ratinaud, M. H. (2006) Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. *Biochem Pharmacol* **71**, 1162-1174
  96. Solazzo, M., Fantappie, O., Lasagna, N., Sassoli, C., Nosi, D., and Mazzanti, R. (2006) P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. *Exp Cell Res* **312**, 4070-4078
  97. Solazzo, M., Fantappie, O., D'Amico, M., Sassoli, C., Tani, A., Cipriani, G., Bogani, C., Formigli, L., and Mazzanti, R. (2009) Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. *Cancer Res* **69**, 7235-7242
  98. Roundhill, E. A., and Burchill, S. A. (2012) Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. *Br J Cancer* **106**, 1224-1233
  99. Elliott, R. L., Jiang, X. P., and Head, J. F. (2012) Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity. *Breast Cancer Res Treat* **136**, 347-354
  100. Suhane, S., and Ramanujan, V. K. (2011) Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. *Biochem Biophys Res Commun* **414**, 73-78
  101. Shin, D. H., Choi, Y. J., and Park, J. W. (2014) SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. *Cancer Res* **74**, 298-308
  102. Shen, Y. C., Ou, D. L., Hsu, C., Lin, K. L., Chang, C. Y., Lin, C. Y., Liu, S. H., and Cheng, A. L. (2013) Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. *Br J Cancer* **108**, 72-81
  103. Xie, J., Wang, B. S., Yu, D. H., Lu, Q., Ma, J., Qi, H., Fang, C., and Chen, H. Z. (2011) Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. *Int J Oncol* **38**, 409-417
  104. Heshe, D., Hoogestraat, S., Brauckmann, C., Karst, U., Boos, J., and Lanvers-Kaminsky, C. (2011) Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. *Cancer Chemother Pharmacol* **67**, 647-655
  105. Hara, K., Kasahara, E., Takahashi, N., Konishi, M., Inoue, J., Jikumaru, M., Kubo, S., Okamura, H., Sato, E., and Inoue, M. (2011) Mitochondria determine the efficacy of anticancer agents that interact with DNA but not the cytoskeleton. *J Pharmacol Exp Ther* **337**, 838-845

106. Alakhova, D. Y., Rapoport, N. Y., Batrakova, E. V., Timoshin, A. A., Li, S., Nicholls, D., Alakhov, V. Y., and Kabanov, A. V. (2010) Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. *Journal of controlled release : official journal of the Controlled Release Society* **142**, 89-100
107. Oliva, C. R., Moellering, D. R., Gillespie, G. Y., and Griguer, C. E. (2011) Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. *PLoS One* **6**, e24665
108. Harper, M. E., Antoniou, A., Villalobos-Menuet, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., Kupperman, J., Newell, E. W., Bernalov, I. A., Wallace, S. S., Liu, Y., Rogers, J. R., Gibbs, G. L., Leahy, J. L., Camley, R. E., Melamed, R., and Newell, M. K. (2002) Characterization of a novel metabolic strategy used by drug-resistant tumor cells. *FASEB J* **16**, 1550-1557
109. Negre-Salvayre, A., Hirtz, C., Carrera, G., Cazenave, R., Troly, M., Salvayre, R., Penicaud, L., and Casteilla, L. (1997) A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. *FASEB J* **11**, 809-815
110. Parker, N., Vidal-Puig, A., and Brand, M. D. (2008) Stimulation of mitochondrial proton conductance by hydroxynonenal requires a high membrane potential. *Biosci Rep* **28**, 83-88
111. Diao, J., Allister, E. M., Koshkin, V., Lee, S. C., Bhattacharjee, A., Tang, C., Giacca, A., Chan, C. B., and Wheeler, M. B. (2008) UCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival. *Proc Natl Acad Sci U S A* **105**, 12057-12062
112. Mailloux, R. J., Adjeitey, C. N., and Harper, M. E. (2010) Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents. *PLoS One* **5**, e13289
113. Pons, D. G., Nadal-Serrano, M., Torrens-Mas, M., Valle, A., Oliver, J., and Roca, P. (2015) UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress. *Free Radic Biol Med* **86**, 67-77
114. Dalla Pozza, E., Fiorini, C., Dando, I., Menegazzi, M., Sgarbossa, A., Costanzo, C., Palmieri, M., and Donadelli, M. (2012) Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. *Biochim Biophys Acta* **1823**, 1856-1863
115. Okon, I. S., Coughlan, K. A., Zhang, M., Wang, Q., and Zou, M. H. (2015) Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells. *J Biol Chem* **290**, 9101-9110
116. Farrand, L., Byun, S., Kim, J. Y., Im-Aram, A., Lee, J., Lim, S., Lee, K. W., Suh, J. Y., Lee, H. J., and Tsang, B. K. (2013) Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. *J Biol Chem* **288**, 23740-23750
117. Santin, G., Piccolini, V. M., Barni, S., Veneroni, P., Giansanti, V., Dal Bo, V., Bernocchi, G., and Bottone, M. G. (2013) Mitochondrial fusion: a mechanism of cisplatin-induced resistance in neuroblastoma cells? *Neurotoxicology* **34**, 51-60
118. Lobo, R. C., Hubbard, N. E., Damonte, P., Mori, H., Penzvalto, Z., Pham, C., Koehne, A. L., Go, A. C., Anderson, S. E., Cala, P. M., and Borowsky, A. D. (2016) Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity. *Frontiers in cell and developmental biology* **4**, 93

119. Anderson, M., Moshnikova, A., Engelman, D. M., Reshetnyak, Y. K., and Andreev, O. A. (2016) Probe for the measurement of cell surface pH in vivo and ex vivo. *Proc Natl Acad Sci U S A* **113**, 8177-8181
120. Longo, D. L., Bartoli, A., Consolino, L., Bardini, P., Arena, F., Schwaiger, M., and Aime, S. (2016) In Vivo Imaging of Tumor Metabolism and Acidosis by Combining PET and MRI-CEST pH Imaging. *Cancer Res*
121. Yamagata, M., Hasuda, K., Stamato, T., and Tannock, I. F. (1998) The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. *Br J Cancer* **77**, 1726-1731
122. Newell, K., Franchi, A., Pouyssegur, J., and Tannock, I. (1993) Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. *Proc Natl Acad Sci U S A* **90**, 1127-1131
123. Helmlinger, G., Sckell, A., Dellian, M., Forbes, N. S., and Jain, R. K. (2002) Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. *Clin Cancer Res* **8**, 1284-1291
124. Kroemer, G., and Pouyssegur, J. (2008) Tumor cell metabolism: cancer's Achilles' heel. *Cancer Cell* **13**, 472-482
125. Cardone, R. A., Casavola, V., and Reshkin, S. J. (2005) The role of disturbed pH dynamics and the Na<sup>+</sup>/H<sup>+</sup> exchanger in metastasis. *Nat Rev Cancer* **5**, 786-795
126. Parks, S. K., Chiche, J., and Pouyssegur, J. (2011) pH control mechanisms of tumor survival and growth. *J Cell Physiol* **226**, 299-308
127. Parks, S. K., and Pouyssegur, J. (2015) The Na<sup>(+)</sup>/HCO<sub>3</sub><sup>(-)</sup> Co-Transporter SLC4A4 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells. *J Cell Physiol* **230**, 1954-1963
128. Counillon, L., and Pouyssegur, J. (2000) The expanding family of eucaryotic Na<sup>(+)</sup>/H<sup>(+)</sup> exchangers. *J Biol Chem* **275**, 1-4
129. Swietach, P., Vaughan-Jones, R. D., and Harris, A. L. (2007) Regulation of tumor pH and the role of carbonic anhydrase 9. *Cancer Metastasis Rev* **26**, 299-310
130. Andersen, A. P., Flinck, M., Oernbo, E. K., Pedersen, N. B., Viuff, B. M., and Pedersen, S. F. (2016) Roles of acid-extruding ion transporters in regulation of breast cancer cell growth in a 3-dimensional microenvironment. *Mol Cancer* **15**, 45
131. Pouyssegur, J., Franchi, A., L'Allemain, G., and Paris, S. (1985) Cytoplasmic pH, a key determinant of growth factor-induced DNA synthesis in quiescent fibroblasts. *FEBS Lett* **190**, 115-119
132. Stock, C., Cardone, R. A., Busco, G., Krahling, H., Schwab, A., and Reshkin, S. J. (2008) Protons extruded by NHE1: digestive or glue? *Eur J Cell Biol* **87**, 591-599
133. Stock, C., and Schwab, A. (2006) Role of the Na/H exchanger NHE1 in cell migration. *Acta Physiol (Oxf)* **187**, 149-157
134. Stock, C., and Schwab, A. (2009) Protons make tumor cells move like clockwork. *Pflugers Arch* **458**, 981-992
135. Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mule, J. J., Ibrahim-Hashim, A., and Gillies, R. J. (2016) Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. *Cancer Res* **76**, 1381-1390
136. Casey, J. R., Grinstein, S., and Orlowski, J. (2010) Sensors and regulators of intracellular pH. *Nat Rev Mol Cell Biol* **11**, 50-61

137. Park, H. J., Lyons, J. C., Ohtsubo, T., and Song, C. W. (1999) Acidic environment causes apoptosis by increasing caspase activity. *Br J Cancer* **80**, 1892-1897
138. Yuan, J., Narayanan, L., Rockwell, S., and Glazer, P. M. (2000) Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. *Cancer Res* **60**, 4372-4376
139. Orłowski, J., and Grinstein, S. (1997) Na<sup>+</sup>/H<sup>+</sup> exchangers of mammalian cells. *J Biol Chem* **272**, 22373-22376
140. Lacroix, J., Poet, M., Maehrel, C., and Counillon, L. (2004) A mechanism for the activation of the Na/H exchanger NHE-1 by cytoplasmic acidification and mitogens. *EMBO Rep* **5**, 91-96
141. Paris, S., and Pouyssegur, J. (1984) Growth factors activate the Na<sup>+</sup>/H<sup>+</sup> antiporter in quiescent fibroblasts by increasing its affinity for intracellular H<sup>+</sup>. *J Biol Chem* **259**, 10989-10994
142. Amith, S. R., Fong, S., Baksh, S., and Fliegel, L. (2015) Na (+)/H (+)exchange in the tumour microenvironment: does NHE1 drive breast cancer carcinogenesis? *The International journal of developmental biology* **59**, 367-377
143. Frantz, C., Karydis, A., Nalbant, P., Hahn, K. M., and Barber, D. L. (2007) Positive feedback between Cdc42 activity and H<sup>+</sup> efflux by the Na-H exchanger NHE1 for polarity of migrating cells. *J Cell Biol* **179**, 403-410
144. Sanhueza, C., Araos, J., Naranjo, L., Toledo, F., Beltran, A. R., Ramirez, M. A., Gutierrez, J., Pardo, F., Leiva, A., and Sobrevia, L. (2016) Sodium/proton exchanger isoform 1 regulates intracellular pH and cell proliferation in human ovarian cancer. *Biochim Biophys Acta* **1863**, 81-91
145. Dykes, S. S., Gao, C., Songock, W. K., Bigelow, R. L., Woude, G. V., Bodily, J. M., and Cardelli, J. A. (2016) Zinc finger E-box binding homeobox-1 (Zeb1) drives anterograde lysosome trafficking and tumor cell invasion via upregulation of Na<sup>+</sup>/H<sup>+</sup> Exchanger-1 (NHE1). *Molecular carcinogenesis*
146. Akram, S., Teong, H. F., Fliegel, L., Pervaiz, S., and Clement, M. V. (2006) Reactive oxygen species-mediated regulation of the Na<sup>+</sup>-H<sup>+</sup> exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. *Cell Death Differ* **13**, 628-641
147. Hardonniere, K., Saunier, E., Lemarie, A., Fernier, M., Gallais, I., Helies-Toussaint, C., Mograbi, B., Antonio, S., Benit, P., Rustin, P., Janin, M., Habarou, F., Ottolenghi, C., Lavault, M. T., Benelli, C., Sergent, O., Huc, L., Bortoli, S., and Lagadic-Gossmann, D. (2016) The environmental carcinogen benzo[a]pyrene induces a Warburg-like metabolic reprogramming dependent on NHE1 and associated with cell survival. *Scientific reports* **6**, 30776
148. Bourguignon, L. Y., Singleton, P. A., Diedrich, F., Stern, R., and Gilad, E. (2004) CD44 interaction with Na<sup>+</sup>-H<sup>+</sup> exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. *J Biol Chem* **279**, 26991-27007
149. Baumgartner, M., Patel, H., and Barber, D. L. (2004) Na(+)/H(+) exchanger NHE1 as plasma membrane scaffold in the assembly of signaling complexes. *Am J Physiol Cell Physiol* **287**, C844-850
150. Beaty, B. T., Wang, Y., Bravo-Cordero, J. J., Sharma, V. P., Miskolci, V., Hodgson, L., and Condeelis, J. (2014) Talin regulates moesin-NHE-1 recruitment to invadopodia and promotes mammary tumor metastasis. *J Cell Biol* **205**, 737-751

151. Choi, C. H., Webb, B. A., Chimenti, M. S., Jacobson, M. P., and Barber, D. L. (2013) pH sensing by FAK-His58 regulates focal adhesion remodeling. *J Cell Biol* **202**, 849-859
152. Liu, H., Stupak, J., Zheng, J., Keller, B. O., Brix, B. J., Fliegel, L., and Li, L. (2004) Open tubular immobilized metal ion affinity chromatography combined with MALDI MS and MS/MS for identification of protein phosphorylation sites. *Analytical chemistry* **76**, 4223-4232
153. Malo, M. E., Li, L., and Fliegel, L. (2007) Mitogen-activated protein kinase-dependent activation of the Na<sup>+</sup>/H<sup>+</sup> exchanger is mediated through phosphorylation of amino acids Ser770 and Ser771. *J Biol Chem* **282**, 6292-6299
154. Karki, P., Li, X., Schrama, D., and Fliegel, L. (2011) B-Raf associates with and activates the NHE1 isoform of the Na<sup>+</sup>/H<sup>+</sup> exchanger. *J Biol Chem* **286**, 13096-13105
155. Roger, S., Gillet, L., Le Guennec, J. Y., and Besson, P. (2015) Voltage-gated sodium channels and cancer: is excitability their primary role? *Front Pharmacol* **6**, 152
156. Roger, S., Potier, M., Vandier, C., Besson, P., and Le Guennec, J. Y. (2006) Voltage-gated sodium channels: new targets in cancer therapy? *Curr Pharm Des* **12**, 3681-3695
157. Roger, S., Rollin, J., Barascu, A., Besson, P., Raynal, P. I., Iochmann, S., Lei, M., Bougnoux, P., Gruel, Y., and Le Guennec, J. Y. (2007) Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. *Int J Biochem Cell Biol* **39**, 774-786
158. Hodgkin, A. L., and Huxley, A. F. (1952) A quantitative description of membrane current and its application to conduction and excitation in nerve. *J Physiol* **117**, 500-544
159. Hodgkin, A. L., and Huxley, A. F. (1952) Propagation of electrical signals along giant nerve fibers. *Proceedings of the Royal Society of London. Series B, Biological sciences* **140**, 177-183
160. Hodgkin, A. L., and Huxley, A. F. (1952) The dual effect of membrane potential on sodium conductance in the giant axon of *Loligo*. *J Physiol* **116**, 497-506
161. Hodgkin, A. L., and Huxley, A. F. (1952) The components of membrane conductance in the giant axon of *Loligo*. *J Physiol* **116**, 473-496
162. Hodgkin, A. L., and Huxley, A. F. (1952) Currents carried by sodium and potassium ions through the membrane of the giant axon of *Loligo*. *J Physiol* **116**, 449-472
163. Hodgkin, A. L., Huxley, A. F., and Katz, B. (1952) Measurement of current-voltage relations in the membrane of the giant axon of *Loligo*. *J Physiol* **116**, 424-448
164. Besson, P., Driffort, V., Bon, E., Gradek, F., Chevalier, S., and Roger, S. (2015) How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells? *Biochim Biophys Acta* **1848**, 2493-2501
165. Brackenbury, W. J. (2012) Voltage-gated sodium channels and metastatic disease. *Channels (Austin)* **6**
166. Yang, M., Kozminski, D. J., Wold, L. A., Modak, R., Calhoun, J. D., Isom, L. L., and Brackenbury, W. J. (2012) Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. *Breast Cancer Res Treat*
167. Fraser, S. P., Diss, J. K., Chioni, A. M., Mycielska, M. E., Pan, H., Yamaci, R. F., Pani, F., Siwy, Z., Krasowska, M., Grzywna, Z., Brackenbury, W. J., Theodorou, D., Koyuturk, M., Kaya, H., Battaloglu, E., De Bella, M. T., Slade, M. J., Tolhurst, R.,

- Palmieri, C., Jiang, J., Latchman, D. S., Coombes, R. C., and Djamgoz, M. B. (2005) Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. *Clin Cancer Res* **11**, 5381-5389
168. Brisson, L., Driffort, V., Benoist, L., Poet, M., Counillon, L., Antelmi, E., Rubino, R., Besson, P., Labbal, F., Chevalier, S., Reshkin, S. J., Gore, J., and Roger, S. (2013) Nav1.5 Na<sup>+</sup> channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia. *J Cell Sci* **126**, 4835-4842
169. Roger, S., Besson, P., and Le Guennec, J. Y. (2003) Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line. *Biochim Biophys Acta* **1616**, 107-111
170. Gillet, L., Roger, S., Besson, P., Lecaille, F., Gore, J., Bougnoux, P., Lalmanach, G., and Le Guennec, J. Y. (2009) Voltage-gated Sodium Channel Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer Cells. *J Biol Chem* **284**, 8680-8691
171. Lecaille, F., Kaleta, J., and Bromme, D. (2002) Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. *Chem Rev* **102**, 4459-4488
172. Brisson, L., Gillet, L., Calaghan, S., Besson, P., Le Guennec, J. Y., Roger, S., and Gore, J. (2011) Nav1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H<sup>+</sup> efflux in caveolae. *Oncogene* **30**, 2070-2076
173. Nelson, M., Yang, M., Millican-Slater, R., and Brackenbury, W. J. (2015) Nav1.5 regulates breast tumor growth and metastatic dissemination in vivo. *Oncotarget* **6**, 32914-32929
174. Driffort, V., Gillet, L., Bon, E., Marionneau-Lambot, S., Oullier, T., Joulin, V., Collin, C., Pages, J. C., Jourdan, M. L., Chevalier, S., Bougnoux, P., Le Guennec, J. Y., Besson, P., and Roger, S. (2014) Ranolazine inhibits Nav1.5-mediated breast cancer cell invasiveness and lung colonization. *Mol Cancer* **13**, 264
175. Xia, J., Huang, N., Huang, H., Sun, L., Dong, S., Su, J., Zhang, J., Wang, L., Lin, L., Shi, M., Bin, J., Liao, Y., Li, N., and Liao, W. (2016) Voltage-gated sodium channel Nav 1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1. *Int J Cancer* **139**, 2553-2569
176. Nelson, M., Yang, M., Dowle, A. A., Thomas, J. R., and Brackenbury, W. J. (2015) The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. *Mol Cancer* **14**, 13
177. Baptista-Hon, D. T., Robertson, F. M., Robertson, G. B., Owen, S. J., Rogers, G. W., Lydon, E. L., Lee, N. H., and Hales, T. G. (2014) Potent inhibition by ropivacaine of metastatic colon cancer SW620 cell invasion and Nav1.5 channel function. *Br J Anaesth* **113 Suppl 1**, i39-i48
178. Kellenberger, S., and Schild, L. (2015) International Union of Basic and Clinical Pharmacology. XCI. structure, function, and pharmacology of acid-sensing ion channels and the epithelial Na<sup>+</sup> channel. *Pharmacol Rev* **67**, 1-35
179. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., and Julius, D. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* **389**, 816-824
180. Tominaga, M., Caterina, M. J., Malmberg, A. B., Rosen, T. A., Gilbert, H., Skinner, K., Raumann, B. E., Basbaum, A. I., and Julius, D. (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron* **21**, 531-543

181. Wang, Y. Y., Chang, R. B., Allgood, S. D., Silver, W. L., and Liman, E. R. (2011) A TRPA1-dependent mechanism for the pungent sensation of weak acids. *J Gen Physiol* **137**, 493-505
182. Wang, Y. Y., Chang, R. B., and Liman, E. R. (2010) TRPA1 is a component of the nociceptive response to CO<sub>2</sub>. *J Neurosci* **30**, 12958-12963
183. Nakanishi, M., Morita, Y., Hata, K., and Muragaki, Y. (2016) Acidic microenvironments induce lymphangiogenesis and IL-8 production via TRPV1 activation in human lymphatic endothelial cells. *Exp Cell Res* **345**, 180-189
184. Wan, Y. (2016) New Mechanism of Bone Cancer Pain: Tumor Tissue-Derived Endogenous Formaldehyde Induced Bone Cancer Pain via TRPV1 Activation. *Adv Exp Med Biol* **904**, 41-58
185. Ruparel, S., Bendele, M., Wallace, A., and Green, D. (2015) Released lipids regulate transient receptor potential channel (TRP)-dependent oral cancer pain. *Molecular pain* **11**, 30
186. Kapoor, N., Lee, W., Clark, E., Bartoszewski, R., McNicholas, C. M., Latham, C. B., Bebok, Z., Parpura, V., Fuller, C. M., Palmer, C. A., and Benos, D. J. (2011) Interaction of ASIC1 and ENaC subunits in human glioma cells and rat astrocytes. *Am J Physiol Cell Physiol* **300**, C1246-1259
187. Chen, K. H., Tung, P. Y., Wu, J. C., Chen, Y., Chen, P. C., Huang, S. H., and Wang, S. M. (2008) An acidic extracellular pH induces Src kinase-dependent loss of beta-catenin from the adherens junction. *Cancer Lett* **267**, 37-48
188. Chen, Y., Chen, C. H., Tung, P. Y., Huang, S. H., and Wang, S. M. (2009) An acidic extracellular pH disrupts adherens junctions in HepG2 cells by Src kinases-dependent modification of E-cadherin. *J Cell Biochem* **108**, 851-859
189. Stock, C., Mueller, M., Kraehling, H., Mally, S., Noel, J., Eder, C., and Schwab, A. (2007) pH nanoenvironment at the surface of single melanoma cells. *Cell Physiol Biochem* **20**, 679-686
190. Peppicelli, S., Bianchini, F., Toti, A., Laurenzana, A., Fibbi, G., and Calorini, L. (2015) Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression. *Cell Cycle* **14**, 3088-3100
191. Corbet, C., Draoui, N., Polet, F., Pinto, A., Drozak, X., Riant, O., and Feron, O. (2014) The SIRT1/HIF2alpha axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. *Cancer Res* **74**, 5507-5519
192. Corbet, C., Pinto, A., Martherus, R., Santiago de Jesus, J. P., Polet, F., and Feron, O. (2016) Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation. *Cell metabolism* **24**, 311-323
193. Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., and Fais, S. (2015) Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. *Drug Resist Updat* **23**, 69-78
194. Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., and Gillies, R. J. (2011) Drug resistance and cellular adaptation to tumor acidic pH microenvironment. *Mol Pharm* **8**, 2032-2038
195. Vukovic, V., and Tannock, I. F. (1997) Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. *Br J Cancer* **75**, 1167-1172
196. Gerweck, L. E., Vijayappa, S., and Kozin, S. (2006) Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. *Mol Cancer Ther* **5**, 1275-1279

197. Mahoney, B. P., Raghunand, N., Baggett, B., and Gillies, R. J. (2003) Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. *Biochem Pharmacol* **66**, 1207-1218
198. Avnet, S., Lemma, S., Cortini, M., Pellegrini, P., Perut, F., Zini, N., Kusuzaki, K., Chano, T., Grisendi, G., Dominici, M., De Milito, A., and Baldini, N. (2016) Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance. *Oncotarget*
199. Gerweck, L. E., and Seetharaman, K. (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. *Cancer Res* **56**, 1194-1198
200. Raghunand, N., Mahoney, B. P., and Gillies, R. J. (2003) Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. *Biochem Pharmacol* **66**, 1219-1229
201. Siemann, D. W., Chapman, M., and Beikirch, A. (1991) Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. *Int J Radiat Oncol Biol Phys* **20**, 287-289
202. Skarsgard, L. D., Skwarchuk, M. W., Vinczan, A., Kristl, J., and Chaplin, D. J. (1995) The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. *Anticancer Res* **15**, 219-223
203. Kroon, H. M., Moncrieff, M., Kam, P. C., and Thompson, J. F. (2008) Outcomes following isolated limb infusion for melanoma. A 14-year experience. *Ann Surg Oncol* **15**, 3003-3013
204. Altan, N., Chen, Y., Schindler, M., and Simon, S. M. (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. *J Exp Med* **187**, 1583-1598
205. Thews, O., Gassner, B., Kelleher, D. K., Schwerdt, G., and Gekle, M. (2006) Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. *Neoplasia* **8**, 143-152
206. Lotz, C., Kelleher, D. K., Gassner, B., Gekle, M., Vaupel, P., and Thews, O. (2007) Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. *Oncol Rep* **17**, 239-244
207. Rauch, C. (2009) Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. *Eur Biophys J* **38**, 829-846
208. Silva, A. S., Yunes, J. A., Gillies, R. J., and Gatenby, R. A. (2009) The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. *Cancer Res* **69**, 2677-2684
209. Raghunand, N., He, X., van Sluis, R., Mahoney, B., Baggett, B., Taylor, C. W., Paine-Murrieta, G., Roe, D., Bhujwala, Z. M., and Gillies, R. J. (1999) Enhancement of chemotherapy by manipulation of tumour pH. *Br J Cancer* **80**, 1005-1011
210. Robey, I. F., Baggett, B. K., Kirkpatrick, N. D., Roe, D. J., Dosesu, J., Sloane, B. F., Hashim, A. I., Morse, D. L., Raghunand, N., Gatenby, R. A., and Gillies, R. J. (2009) Bicarbonate increases tumor pH and inhibits spontaneous metastases. *Cancer Res* **69**, 2260-2268



211. Ribeiro, M. D., Silva, A. S., Bailey, K. M., Kumar, N. B., Sellers, T. A., Gatenby, R. A., Ibrahim-Hashim, A., and Gillies, R. J. (2012) Buffer Therapy for Cancer. *J Nutr Food Sci* **2**, 6
212. Yu, M., Lee, C., Wang, M., and Tannock, I. F. (2015) Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. *Cancer Sci* **106**, 1438-1447
213. Klionsky, D. J. (2008) Autophagy revisited: a conversation with Christian de Duve. *Autophagy* **4**, 740-743
214. Yang, Z., and Klionsky, D. J. (2010) Eaten alive: a history of macroautophagy. *Nat Cell Biol* **12**, 814-822
215. Rubinsztein, D. C., Codogno, P., and Levine, B. (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat Rev Drug Discov* **11**, 709-730
216. Weidberg, H., Shvets, E., and Elazar, Z. (2011) Biogenesis and cargo selectivity of autophagosomes. *Annu Rev Biochem* **80**, 125-156
217. Kim, K. H., and Lee, M. S. (2014) Autophagy--a key player in cellular and body metabolism. *Nat Rev Endocrinol* **10**, 322-337
218. Pang, M., Wang, H., Rao, P., Zhao, Y., Xie, J., Cao, Q., Wang, Y., Wang, Y. M., Lee, V. W., Alexander, S. I., Harris, D. C., and Zheng, G. (2016) Autophagy links beta-catenin and Smad signaling to promote epithelial-mesenchymal transition via upregulation of integrin linked kinase. *Int J Biochem Cell Biol* **76**, 123-134
219. Jiang, Y., Woosley, A. N., Sivalingam, N., Natarajan, S., and Howe, P. H. (2016) Cathepsin-B-mediated cleavage of Disabled-2 regulates TGF-beta-induced autophagy. *Nat Cell Biol* **18**, 851-863
220. Kaushik, S., Bandyopadhyay, U., Sridhar, S., Kiffin, R., Martinez-Vicente, M., Kon, M., Orenstein, S. J., Wong, E., and Cuervo, A. M. (2011) Chaperone-mediated autophagy at a glance. *J Cell Sci* **124**, 495-499
221. Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S., Natsume, T., Takehana, K., Yamada, N., Guan, J. L., Oshiro, N., and Mizushima, N. (2009) Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. *Mol Biol Cell* **20**, 1981-1991
222. Jung, C. H., Jun, C. B., Ro, S. H., Kim, Y. M., Otto, N. M., Cao, J., Kundu, M., and Kim, D. H. (2009) ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. *Mol Biol Cell* **20**, 1992-2003
223. Mizushima, N., and Komatsu, M. (2011) Autophagy: renovation of cells and tissues. *Cell* **147**, 728-741
224. Rao, S., Tortola, L., Perlot, T., Wirnsberger, G., Novatchkova, M., Nitsch, R., Sykacek, P., Frank, L., Schramek, D., Komnenovic, V., Sigl, V., Aumayr, K., Schmauss, G., Fellner, N., Handschuh, S., Glosmann, M., Pasierbek, P., Schleder, M., Resch, G. P., Ma, Y., Yang, H., Popper, H., Kenner, L., Kroemer, G., and Penninger, J. M. (2014) A dual role for autophagy in a murine model of lung cancer. *Nature communications* **5**, 3056
225. White, E. (2015) The role for autophagy in cancer. *J Clin Invest* **125**, 42-46
226. Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci U S A* **100**, 15077-15082
227. Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., and Levine, B. (2003)

- Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Invest* **112**, 1809-1820
228. Strohecker, A. M., Guo, J. Y., Karsli-Uzunbas, G., Price, S. M., Chen, G. J., Mathew, R., McMahon, M., and White, E. (2013) Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. *Cancer Discov* **3**, 1272-1285
  229. Guo, J. Y., Teng, X., Laddha, S. V., Ma, S., Van Nostrand, S. C., Yang, Y., Khor, S., Chan, C. S., Rabinowitz, J. D., and White, E. (2016) Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. *Genes & development* **30**, 1704-1717
  230. Brisson, L., Banski, P., Sboarina, M., Dethier, C., Danhier, P., Fontenille, M. J., Van Hee, V. F., Vazeille, T., Tardy, M., Falces, J., Bouzin, C., Porporato, P. E., Frederick, R., Michiels, C., Copetti, T., and Sonveaux, P. (2016) Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer. *Cancer Cell* **30**, 418-431
  231. Dechant, R., Binda, M., Lee, S. S., Pelet, S., Winderickx, J., and Peter, M. (2010) Cytosolic pH is a second messenger for glucose and regulates the PKA pathway through V-ATPase. *EMBO J* **29**, 2515-2526
  232. Dechant, R., and Peter, M. (2011) The N-terminal domain of the V-ATPase subunit 'a' is regulated by pH in vitro and in vivo. *Channels (Austin)* **5**, 4-8
  233. Dechant, R., Saad, S., Ibanez, A. J., and Peter, M. (2014) Cytosolic pH regulates cell growth through distinct GTPases, Arf1 and Gtr1, to promote Ras/PKA and TORC1 activity. *Mol Cell* **55**, 409-421
  234. Dechant, R., and Peter, M. (2014) Cytosolic pH: A conserved regulator of cell growth? *Mol Cell Oncol* **1**, e969643
  235. Efeyan, A., Zoncu, R., Chang, S., Gumper, I., Snitkin, H., Wolfson, R. L., Kirak, O., Sabatini, D. D., and Sabatini, D. M. (2013) Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. *Nature* **493**, 679-683
  236. Bar-Peled, L., and Sabatini, D. M. (2014) Regulation of mTORC1 by amino acids. *Trends Cell Biol* **24**, 400-406
  237. Balgi, A. D., Diering, G. H., Donohue, E., Lam, K. K., Fonseca, B. D., Zimmerman, C., Numata, M., and Roberge, M. (2011) Regulation of mTORC1 signaling by pH. *PLoS One* **6**, e21549
  238. Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., Wang, X., He, C., and Pan, H. (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. *Cell Death Dis* **4**, e838
  239. Marino, M. L., Pellegrini, P., Di Lernia, G., Djavaheri-Mergny, M., Brnjic, S., Zhang, X., Hagg, M., Linder, S., Fais, S., Codogno, P., and De Milito, A. (2012) Autophagy is a protective mechanism for human melanoma cells under acidic stress. *J Biol Chem* **287**, 30664-30676
  240. Wojtkowiak, J. W., Rothberg, J. M., Kumar, V., Schramm, K. J., Haller, E., Proemsey, J. B., Lloyd, M. C., Sloane, B. F., and Gillies, R. J. (2012) Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. *Cancer Res* **72**, 3938-3947
  241. Xu, T., Su, H., Ganapathy, S., and Yuan, Z. M. (2011) Modulation of autophagic activity by extracellular pH. *Autophagy* **7**, 1316-1322
  242. Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., and Thompson, C. B. (2007) Autophagy inhibition enhances

- therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest* **117**, 326-336
243. Duffy, A., Le, J., Sausville, E., and Emadi, A. (2015) Autophagy modulation: a target for cancer treatment development. *Cancer Chemother Pharmacol* **75**, 439-447
244. Pellegrini, P., Strambi, A., Zipoli, C., Hagg-Olofsson, M., Buoncervello, M., Linder, S., and De Milito, A. (2014) Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies. *Autophagy* **10**, 562-571
245. Pellegrini, P., Dyczynski, M., Sbrana, F. V., Karlgren, M., Buoncervello, M., Hagg-Olofsson, M., Ma, R., Hartman, J., Bajalica-Lagercrantz, S., Grandner, D., Kharaziha, P., and De Milito, A. (2016) Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. *Oncotarget* **7**, 35703-35723
246. Jangamreddy, J. R., Panigrahi, S., and Los, M. J. (2015) Monitoring of autophagy is complicated--salinomycin as an example. *Biochim Biophys Acta* **1853**, 604-610
247. Apel, A., Herr, I., Schwarz, H., Rodemann, H. P., and Mayer, A. (2008) Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. *Cancer Res* **68**, 1485-1494
248. Lomonaco, S. L., Finniss, S., Xiang, C., Decarvalho, A., Umansky, F., Kalkanis, S. N., Mikkelsen, T., and Brodie, C. (2009) The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. *Int J Cancer* **125**, 717-722
249. Paglin, S., Hollister, T., Delohery, T., Hackett, N., McMahon, M., Sphicas, E., Domingo, D., and Yahalom, J. (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. *Cancer Res* **61**, 439-444
250. Paglin, S., Lee, N. Y., Nakar, C., Fitzgerald, M., Plotkin, J., Deuel, B., Hackett, N., McMahon, M., Sphicas, E., Lampen, N., and Yahalom, J. (2005) Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. *Cancer Res* **65**, 11061-11070
251. Soto-Pantoja, D. R., Miller, T. W., Pendrak, M. L., DeGraff, W. G., Sullivan, C., Ridnour, L. A., Abu-Asab, M., Wink, D. A., Tsokos, M., and Roberts, D. D. (2012) CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. *Autophagy* **8**, 1628-1642
252. Kroemer, G., and Levine, B. (2008) Autophagic cell death: the story of a misnomer. *Nat Rev Mol Cell Biol* **9**, 1004-1010
253. Shen, S., Kepp, O., and Kroemer, G. (2012) The end of autophagic cell death? *Autophagy* **8**, 1-3
254. Wang, Y., Zhang, N., Zhang, L., Li, R., Fu, W., Ma, K., Li, X., Wang, L., Wang, J., Zhang, H., Gu, W., Zhu, W. G., and Zhao, Y. (2016) Autophagy Regulates Chromatin Ubiquitination in DNA Damage Response through Elimination of SQSTM1/p62. *Mol Cell* **63**, 34-48
255. Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., Mikkelsen, T., Wang, D., Chang, Y. C., Hu, J., McAfee, Q., Fisher, J., Troxel, A. B., Piao, S., Heitjan, D. F., Tan, K. S., Pontiggia, L., O'Dwyer, P. J., Davis, L. E., and Amaravadi, R. K. (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. *Autophagy* **10**, 1359-1368

256. Ohtsubo, T., Igawa, H., Saito, T., Matsumoto, H., Park, H. J., Song, C. W., Kano, E., and Saito, H. (2001) Acidic environment modifies heat- or radiation-induced apoptosis in human maxillary cancer cells. *Int J Radiat Oncol Biol Phys* **49**, 1391-1398
257. Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., Federici, C., Iessi, E., Parmiani, G., Arancia, G., Belardelli, F., and Fais, S. (2004) Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. *J Natl Cancer Inst* **96**, 1702-1713
258. Tan, Q., Joshua, A. M., Saggari, J. K., Yu, M., Wang, M., Kanga, N., Zhang, J. Y., Chen, X., Wouters, B. G., and Tannock, I. F. (2015) Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. *Br J Cancer* **112**, 832-840
259. Galluzzi, L., Pedro, J. M., Demaria, S., Formenti, S. C., and Kroemer, G. (2016) Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. *Nat Rev Clin Oncol*
260. Lauritzen, G., Jensen, M. B., Boedtker, E., Dybboe, R., Aalkjaer, C., Nylandsted, J., and Pedersen, S. F. (2010) NBCn1 and NHE1 expression and activity in DeltaNERbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance. *Exp Cell Res* **316**, 2538-2553
261. Cardone, R. A., Greco, M. R., Zeeberg, K., Zaccagnino, A., Saccomano, M., Bellizzi, A., Bruns, P., Menga, M., Pilarsky, C., Schwab, A., Alves, F., Kalthoff, H., Casavola, V., and Reshkin, S. J. (2015) A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. *Neoplasia* **17**, 155-166
262. Amith, S. R., Wilkinson, J. M., Baksh, S., and Fliegel, L. (2015) The Na(+)/H(+) exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells. *Oncotarget* **6**, 1262-1275
263. Rose, D. P., Connolly, J. M., and Coleman, M. (1996) Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. *Clin Cancer Res* **2**, 1751-1756
264. Bounoux, P., Hajjaji, N., Maheo, K., Couet, C., and Chevalier, S. (2010) Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. *Prog Lipid Res* **49**, 76-86
265. Bounoux, P. (1999) n-3 polyunsaturated fatty acids and cancer. *Curr Opin Clin Nutr Metab Care* **2**, 121-126
266. Eltweri, A. M., Thomas, A. L., Metcalfe, M., Calder, P. C., Dennison, A. R., and Bowrey, D. J. (2016) Potential applications of fish oils rich in omega-3 polyunsaturated fatty acids in the management of gastrointestinal cancer. *Clinical nutrition*
267. Yan, G., Li, L., Zhu, B., and Li, Y. (2016) Lipidome in colorectal cancer. *Oncotarget* **7**, 33429-33439
268. Moreel, X., Allaire, J., Leger, C., Caron, A., Labonte, M. E., Lamarche, B., Julien, P., Desmeules, P., Tetu, B., and Fradet, V. (2014) Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. *Cancer prevention research* **7**, 766-776

269. Aucoin, M., Cooley, K., Knee, C., Fritz, H., Balneaves, L. G., Breau, R., Fergusson, D., Skidmore, B., Wong, R., and Seely, D. (2016) Fish-Derived Omega-3 Fatty Acids and Prostate Cancer: A Systematic Review. *Integrative cancer therapies*
270. Bougnoux, P., Giraudeau, B., and Couet, C. (2006) Diet, cancer, and the lipidome. *Cancer Epidemiol Biomarkers Prev* **15**, 416-421
271. Bougnoux, P., Hajjaji, N., and Couet, C. (2008) The lipidome as a composite biomarker of the modifiable part of the risk of breast cancer. *Prostaglandins Leukot Essent Fatty Acids* **79**, 93-96
272. Ouldamer, L., Goupille, C., Vilde, A., Arbion, F., Body, G., Chevalier, S., Cottier, J. P., and Bougnoux, P. (2016) N-3 Polyunsaturated Fatty Acids of Marine Origin and Multifocality in Human Breast Cancer. *PLoS One* **11**, e0147148
273. Barascu, A., Besson, P., Le Floch, O., Bougnoux, P., and Jourdan, M. L. (2005) CDK1-cyclin B1 mediates the inhibition of proliferation induced by omega-3 fatty acids in MDA-MB-231 breast cancer cells. *Int J Biochem Cell Biol*
274. Hajjaji, N., Besson, P., and Bougnoux, P. (2012) Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats. *Cancer Chemother Pharmacol* **70**, 17-23
275. Hajjaji, N., Schubnel, V., and Bougnoux, P. (2011) Determinants of DHA incorporation into tumor tissue during dietary DHA supplementation. *Lipids* **46**, 1063-1069
276. Ouldamer, L., Nadal-Desbarats, L., Chevalier, S., Body, G., Goupille, C., and Bougnoux, P. (2016) NMR-Based Lipidomic Approach To Evaluate Controlled Dietary Intake of Lipids in Adipose Tissue of a Rat Mammary Tumor Model. *Journal of proteome research* **15**, 868-878
277. Wannous, R., Bon, E., Maheo, K., Goupille, C., Chamouton, J., Bougnoux, P., Roger, S., Besson, P., and Chevalier, S. (2013) PPARbeta mRNA expression, reduced by n-3 PUFA diet in mammary tumor, controls breast cancer cell growth. *Biochim Biophys Acta* **1831**, 1618-1625
278. Chauvin, L., Goupille, C., Blanc, C., Pinault, M., Domingo, I., Guimaraes, C., Bougnoux, P., Chevalier, S., and Maheo, K. (2016) Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCepsilon/delta-induced ERK pathways. *Biochim Biophys Acta* **1861**, 380-390
279. Kornfeld, S., Goupille, C., Vibet, S., Chevalier, S., Pinet, A., Lebeau, J., Tranquart, F., Bougnoux, P., Martel, E., Maurin, A., Richard, S., Champeroux, P., and Maheo, K. (2012) Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance. *Carcinogenesis* **33**, 260-267
280. Maheo, K., Chevalier, S., Vibet, S., Bougnoux, P., Richard, S., Serriere, S., Bleuzen, A., Tranquart, F., and Goupille, C. (2012) Non-invasive quantification of tumor vascular architecture during docetaxel-chemotherapy. *Breast Cancer Res Treat* **134**, 1013-1025
281. Goupille, C., Chauvin, L., Vibet, S., Kornfeld, S., Domingo, I., Champeroux, P., Bougnoux, P., Frank, P. G., Chevalier, S., and Mahéo, K. (2016) Remodeling of the vascular network architecture in mammary tumors: role of epiregulin, an antiangiogenic effector of DHA. *PLoS One* **In revision**

282. Zhang, Y., Han, L., Qi, W., Cheng, D., Ma, X., Hou, L., Cao, X., and Wang, C. (2015) Eicosapentaenoic acid (EPA) induced apoptosis in HepG2 cells through ROS-Ca(2+)-JNK mitochondrial pathways. *Biochem Biophys Res Commun* **456**, 926-932
283. Abdi, J., Garssen, J., Faber, J., and Redegeld, F. A. (2014) Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. *J Nutr Biochem* **25**, 1254-1262
284. Rohrbach, S. (2009) Effects of dietary polyunsaturated fatty acids on mitochondria. *Curr Pharm Des* **15**, 4103-4116
285. Agnihotri, N., Sharma, G., Rani, I., Renuka, and Bhatnagar, A. (2016) Fish oil prevents colon cancer by modulation of structure and function of mitochondria. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* **82**, 90-97
286. Zhao, H., Pflug, B. R., Lai, X., and Wang, M. (2016) Pyruvate dehydrogenase alpha 1 as a target of omega-3 polyunsaturated fatty acids in human prostate cancer through a global phosphoproteomic analysis. *Proteomics* **16**, 2419-2431
287. Mouradian, M., Kikawa, K. D., Dranka, B. P., Komasa, S. M., Kalyanaraman, B., and Pardini, R. S. (2015) Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function. *Molecular carcinogenesis* **54**, 810-820
288. Manzi, L., Costantini, L., Molinari, R., and Merendino, N. (2015) Effect of Dietary omega-3 Polyunsaturated Fatty Acid DHA on Glycolytic Enzymes and Warburg Phenotypes in Cancer. *BioMed research international* **2015**, 137097
289. Jing, K., Song, K. S., Shin, S., Kim, N., Jeong, S., Oh, H. R., Park, J. H., Seo, K. S., Heo, J. Y., Han, J., Park, J. I., Han, C., Wu, T., Kweon, G. R., Park, S. K., Yoon, W. H., Hwang, B. D., and Lim, K. (2011) Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. *Autophagy* **7**, 1348-1358
290. Tylichova, Z., Strakova, N., Vondracek, J., Vaculova, A. H., Kozubik, A., and Hofmanova, J. (2017) Activation of autophagy and PPARgamma protect colon cancer cells against apoptosis induced by interactive effects of butyrate and DHA in a cell type-dependent manner: The role of cell differentiation. *J Nutr Biochem* **39**, 145-155
291. Pettersen, K., Mosen, V. T., Hakvag Pettersen, C. H., Overland, H. B., Pettersen, G., Samdal, H., Tesfahun, A. N., Lundemo, A. G., Bjorkoy, G., and Schonberg, S. A. (2016) DHA-induced stress response in human colon cancer cells - Focus on oxidative stress and autophagy. *Free Radic Biol Med* **90**, 158-172
292. D'Eliseo, D., Di Rocco, G., Loria, R., Soddu, S., Santoni, A., and Velotti, F. (2016) Epithelial-to-mesenchymal transition and invasion are upmodulated by tumor-expressed granzyme B and inhibited by docosahexaenoic acid in human colorectal cancer cells. *J Exp Clin Cancer Res* **35**, 24
293. Yin, X., Yu, X. W., Zhu, P., Zhang, Y. M., Zhang, X. H., Wang, F., Zhang, J. J., Yan, W., Xi, Y., Wan, J. B., Kang, J. X., Zou, Z. Q., and Bu, S. Z. (2016) Endogenously synthesized n-3 fatty acids in fat-1 transgenic mice prevent melanoma progression by increasing E-cadherin expression and inhibiting beta-catenin signaling. *Molecular medicine reports* **14**, 3476-3484
294. Blanckaert, V., Ulmann, L., Mimouni, V., Antol, J., Brancquart, L., and Chenais, B. (2010) Docosahexaenoic acid intake decreases proliferation, increases apoptosis and decreases the invasive potential of the human breast carcinoma cell line MDA-MB-231. *Int J Oncol* **36**, 737-742

295. Gillet, L., Roger, S., Bougnoux, P., Le Guennec, J. Y., and Besson, P. (2011) Beneficial effects of omega-3 long-chain fatty acids in breast cancer and cardiovascular diseases: voltage-gated sodium channels as a common feature? *Biochimie* **93**, 4-6
296. Rose, D. P., Connolly, J. M., and Liu, X. H. (1997) Fatty acid regulation of breast cancer cell growth and invasion. *Adv Exp Med Biol* **422**, 47-55
297. Rose, D. P., Rayburn, J., Hatala, M. A., and Connolly, J. M. (1994) Effects of dietary fish oil on fatty acids and eicosanoids in metastasizing human breast cancer cells. *Nutr Cancer* **22**, 131-141
298. Kumar, A. P., Quake, A. L., Chang, M. K., Zhou, T., Lim, K. S., Singh, R., Hewitt, R. E., Salto-Tellez, M., Pervaiz, S., and Clement, M. V. (2009) Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. *Cancer Res* **69**, 8636-8644
299. Besson, P., Gore, J., Vincent, E., Hoinard, C., and Bougnoux, P. (1996) Inhibition of Na<sup>+</sup>/H<sup>+</sup> exchanger activity by an alkyl-lysophospholipid analogue in a human breast cancer cell line. *Biochem Pharmacol* **51**, 1153-1158
300. Lacroix, J., Poet, M., Huc, L., Morello, V., Djerbi, N., Ragno, M., Rissel, M., Tekpli, X., Gounon, P., Lagadic-Gossmann, D., and Counillon, L. (2008) Kinetic analysis of the regulation of the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE-1 by osmotic shocks. *Biochemistry* **47**, 13674-13685
301. Tillman, T. S., and Cascio, M. (2003) Effects of membrane lipids on ion channel structure and function. *Cell Biochem Biophys* **38**, 161-190
302. Jude, S., Bedut, S., Roger, S., Pinault, M., Champeroux, P., White, E., and Le Guennec, J. Y. (2003) Peroxidation of docosahexaenoic acid is responsible for its effects on ITO and ISS in rat ventricular myocytes. *Br J Pharmacol* **139**, 816-822
303. Yaqoob, P., and Shaikh, S. R. (2010) The nutritional and clinical significance of lipid rafts. *Curr Opin Clin Nutr Metab Care* **13**, 156-166
304. Dendele, B., Tekpli, X., Hardonniere, K., Holme, J. A., Debure, L., Catheline, D., Arlt, V. M., Nagy, E., Phillips, D. H., Ovrebo, S., Mollerup, S., Poet, M., Chevanne, M., Rioux, V., Dimanche-Boitrel, M. T., Sergeant, O., and Lagadic-Gossmann, D. (2014) Protective action of n-3 fatty acids on benzo[a]pyrene-induced apoptosis through the plasma membrane remodeling-dependent NHE1 pathway. *Chem Biol Interact* **207**, 41-51
305. House, C. D., Vaske, C. J., Schwartz, A. M., Obias, V., Frank, B., Luu, T., Sarvazyan, N., Irby, R., Strausberg, R. L., Hales, T. G., Stuart, J. M., and Lee, N. H. (2010) Voltage-gated Na<sup>+</sup> channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. *Cancer Res* **70**, 6957-6967
306. House, C. D., Wang, B. D., Ceniccola, K., Williams, R., Simaan, M., Olender, J., Patel, V., Baptista-Hon, D. T., Annunziata, C. M., Gutkind, J. S., Hales, T. G., and Lee, N. H. (2015) Voltage-gated Na<sup>+</sup> Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling. *Scientific reports* **5**, 11541
307. Kang, J. X., and Leaf, A. (1996) Evidence that free polyunsaturated fatty acids modify Na<sup>+</sup> channels by directly binding to the channel proteins. *Proc Natl Acad Sci U S A* **93**, 3542-3546

308. Kang, J. X., Li, Y., and Leaf, A. (1997) Regulation of sodium channel gene expression by class I antiarrhythmic drugs and n - 3 polyunsaturated fatty acids in cultured neonatal rat cardiac myocytes. *Proc Natl Acad Sci U S A* **94**, 2724-2728
309. Pignier, C., Revenaz, C., Raully-Lestienne, I., Cussac, D., Delhon, A., Gardette, J., and Le Grand, B. (2007) Direct protective effects of poly-unsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current: a mechanism for ischemia selectivity. *Basic Res Cardiol* **102**, 553-564
310. Xiao, Y. F., Ke, Q., Wang, S. Y., Auktor, K., Yang, Y., Wang, G. K., Morgan, J. P., and Leaf, A. (2001) Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na<sup>+</sup> channels. *Proc Natl Acad Sci U S A* **98**, 3606-3611
311. Xiao, Y. F., Wright, S. N., Wang, G. K., Morgan, J. P., and Leaf, A. (1998) Fatty acids suppress voltage-gated Na<sup>+</sup> currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na<sup>+</sup> channel. *Proc Natl Acad Sci U S A* **95**, 2680-2685
312. Wannous, R., Bon, E., Gillet, L., Chamouton, J., Weber, G., Brisson, L., Gore, J., Bougnoux, P., Besson, P., Roger, S., and Chevalier, S. (2015) Suppression of PPARbeta, and DHA treatment, inhibit NaV1.5 and NHE-1 pro-invasive activities. *Pflugers Arch* **467**, 1249-1259
313. Isbilen, B., Fraser, S. P., and Djamgoz, M. B. (2006) Docosahexaenoic acid (omega-3) blocks voltage-gated sodium channel activity and migration of MDA-MB-231 human breast cancer cells. *Int J Biochem Cell Biol* **38**, 2173-2182



## **Figure legends:**

### **Figure 1: The gain of invasive capacities in carcinoma cells**

The acquisition of an invasive phenotype in carcinoma cells is associated with the epithelial-to-mesenchymal transition (EMT), a process characterized by the loss of functional apico-basal polarity, the loss of cell-to-cell adhesions (loss of ZO-1 and E-cadherins), the remodelling of the actin cytoskeleton (with the loss of the submembrane cortical F-actin network to the profit of actin stress fibers), the secretion of extracellular matrix (ECM)-degrading proteases (such as matrix metalloproteinases (MMP) and cathepsins). Invasive carcinoma cells that underwent the EMT display a rear-leading-edge polarity, representative of mesenchymal cells, and develop invasive structures, called invadopodia, where is performed the proteolysis of the ECM. In this new cell phenotype, there is redistribution of existing ion channels and transporters, such as the  $\text{Na}^+\text{-H}^+$  exchanger type 1 (NHE1) expressed in baso-lateral side of normal epithelial cells that is translocated to the leading edge and to invadopodia of invasive carcinoma cells. There is also the over-expression of some ion channels such as voltage-gated sodium channels ( $\text{Na}_v$ ) in invadopodia.  $\text{Na}_v$  activity promotes invadopodial formation and ECM proteolytic activity through the Src-dependent phosphorylation of the actin-nucleating promoting factor cortactin (at Y421), resulting in actin polymerisation, and the increase of  $\text{H}^+$  efflux through NHE1, the acidification of the extracellular microenvironment, resulting in protease activation.

### **Figure 2: Cancer cell metabolism and the increased production of protons promote tumour progression**

Under hypoxia, cancer cells are selected on their capacity to produce ATP through the glycolysis. They generally keep this preferred metabolism even in normoxic conditions, a situation called “aerobic glycolysis” (or Warburg effect). This is associated with the increase in glucose transporter 1 (GLUT1) and glycolytic enzymes expression, that is mediated through the stabilization of the hypoxia-sensitive transcription factor HIF1 $\alpha$ , and the increase in the production of H<sup>+</sup>. HIF1 $\alpha$  also promotes the epithelial-to-mesenchymal transition (MET) through the expression of EMT transcription factors (Zeb1/2, Snail 1/2, Twist, ...), leading to the down-regulation of epithelial markers (such as Zonula Occludens 1, ZO-1, and epithelial cadherin, E-Cadh) and the up-regulation of mesenchymal markers (such as vimentin and the neuronal cadherin, N-Cadh). High amounts of CO<sub>2</sub>-derived protons are generated by the mitochondrial activity (tricarboxylic acid (TCA) cycle) and the pentose phosphate pathway. The efflux of H<sup>+</sup>, mediated by several plasma membrane transporters (such as NHE1, V-ATPase, MCT...), permits cancer cell survival and proliferation, favours the acquisition of migrative and invasive properties and inhibits anti-cancer immune response. Voltage-gated sodium channels (Na<sub>v</sub>1.5 and Na<sub>v</sub>1.7) increase the activity of NHE1 and promote cancer cell invasiveness through the proteolytic degradation of the ECM. Protons that are intracellularly produced are also transported to autophagolysosomes to support autophagy and cancer cell survival under nutrient deprivation or anticancer treatment. Extracellular acidification reduces chemotherapy efficacy by limiting the diffusion of some chemotherapeutic agents (such as anthracyclines) and by overactivating the activity of the plasma membrane efflux pump P-glycoprotein (P-gp). Chemotherapy efficacy is also limited by the expression of P-gp at mitochondrial membranes and by the mitochondrial bioenergetics activity (oxidative phosphorylation, OXPHOS).

**Figure 3: Proposed anti-tumour effects of dietary n-3 polyunsaturated fatty acids (n-3 PUFA)**

Dietary n-3 PUFA can, directly or after their being stored under the form of triacylglycerids in adipose tissues, interfere with the carcinogenesis of epithelial tissues and tumour progression. They are proposed to inhibit tumour progression through the inhibition of tumour inflammation, the inhibition of primary tumour growth, the reduction of local invasion, the prevention of metastases development or relapse, and to improve anticancer treatment by limiting chemoresistance.